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Gastric cancer is the second leading cause of cancer death worldwide, 
but has been little studied compared with many other tumors. Copy number 
alteration (CNA) and loss of heterozygosity (LOH) are two common events 
that are related to the tumorigenesis in gastric cancer. LOH is a genetic 
abnormality that causes the loss of one normal allele of a specific gene when 
the other allele has already been mutated. LOH can result in the inactivation of 
tumor suppressor genes (TSGs), and therefore, regions that are frequently and 
independently subject to LOH often harbor TSGs. So far, however, there have 
been few systematic, genome-wide studies of LOH in gastric cancer. Here we 
report the results of genome-wide assessments of CNAs and LOH in 45 gastric 
tumors assayed by Affymetrix SNP 6.0 arrays, each with matched non-
malignant DNA. Analysis of regions that frequently undergo LOH in these 45 
tumors implicates TSGs already known to contribute to gastric carcinogenesis; 
these include TP53 (80%), CDKN2A (67%) and APC (53%). This analysis 
also implicates several candidate TSGs that, to our knowledge, have not been 
previously linked to gastric carcinogenesis. These genes include PTPRD and 
DOCK8 on chromosome 9p. In addition, we unexpectedly found that the 
extent of LOH in tumors is highly correlated with gender and with tumor 
subtypes. These correlations may reflect underlying differences in the 
mechanisms of cancer development and progression. 
Because the accuracy of inference of copy number alteration, LOH, 
and allelic imbalance from SNP arrays mainly depends on the software 
applied, we compared eight commonly used free programs with respect to 
ix 
 
their sensitivities and specificities. We concluded that ASCAT and CNAG 
outperformed the other methods.   
Finally, our analysis of LOH facilitated and supported the discoveries 
of novel TSGs in gastric carcinoma and cholangiocarcinoma (bile duct cancer) 
by next-generation whole-exome sequencing. We also show that one of the 
analytical methods that we studied, ASCAT, can be applied not only to SNP-
array data, but also to next-generation sequencing data. 
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CHAPTER 1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Aims and Outlines 
Gastric cancer is a complex disease with high mortality. It is the second most 
common cause of cancer death worldwide [1], and the five year survival rate for patients 
with the late stage of cancer is ～4% [2]. The effects of treatment are very limited, 
partially due to the intrinsic heterogeneity of the cancer.  Therefore, it is important to 
understand the mechanisms of gastric cancer comprehensively in order to develop more 
effective therapy. 
Tumorigenesis in gastric cancer is caused primarily by genetic alterations [3]. 
Tumorigenesis is marked by the aberrant regulation of genes that are involved in different 
signaling pathways such as cell proliferation and apoptosis. The aberrations include 
genome copy number changes, chromosomal translocations, single nucleotide 
substitutions, epigenetic modifications, insertions-deletions, and loss of heterozygosity 
(LOH). 
LOH is a type of genetic alteration that often provides the second hit of 
tumorigenesis in the Knudson two-hit model of tumorigenesis. In the model, the first hit 
is a mutation on one allele of a gene, and LOH will cost the loss of the other wild-type 
allele [4]. The detection of LOH in tumors facilitates the discovery of tumor suppressor 
genes (TSGs) since TSGs are often located in regions that recurrently undergo LOH. In 
general, at the cellular level, mutations in tumor suppressor genes are recessive, and cells 
that contain one normal and one mutated gene copy still behave normally. However, 
LOH causes cells to lose the remaining normal gene and thus to develop into a tumor. 
TSGs play a key role in carcinogenesis and tumor progression, but our understanding of 
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TSGs is still limited. While some commonly mutated TSGs have been well studied, there 
is evidence that more remain to be discovered. The development of SNP arrays and the 
analytical approaches facilitate the discovery of regions that frequently undergo LOH in 
gastric cancer, which can lead to the discovery of regions containing TSGs.  Therefore, it 
would be of great significance to understand the pattern of recurrent LOH in gastric 
cancer.  
Since few studies of gastric cancer LOH have been undertaken, our aim is to 
understand the effect of LOH in tumorigenesis through a comprehensive genome-wide 
study, and a detailed study of LOH in gastric cancer may present potential biomarkers for 
prognosis and treatment. In addition, we aim to find novel tumor suppressor genes in 
LOH regions and to understand the effect of these genes on gastric cancer development. 
In the current chapter, we provide the background information regarding gastric 
cancer epidemiology and pathology, LOH and the Affymetrix SNP 6.0 array platform 
that we used for whole-genome copy number and LOH analysis.  
In Chapter 2, we focus on the analysis of data of gastric cancer tumor-normal 
pairs with the Affymetrix Genomewide SNP 6.0 platform. We present for the first time a 
whole-genome LOH map of gastric cancer and evidence for several novel tumor 
suppressor genes that may play a key role in tumorigenesis. We also showed a significant 
correlation between LOH and other genetic alterations.  
In Chapter 3, we investigate the application of diverse approaches to copy number 
and LOH analysis and discussed the sensitivity and specificity of these approaches as 
affected by different tumor content.  
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In addition to the genomic alteration analysis in gastric cancer, in Chapter 4, we 
also present the application of LOH analysis to other types of cancers, which aids the 
discoveries of novel TSGs in the respective cancer types. We also show that the 
analytical methods of LOH on SNP 6.0 arrays can be adapted to next-generation 
sequencing data. 
1.2 General Introduction of Gastric Cancer 
1.2.1 Epidemiology 
Gastric Cancer was the fourth most common cancer in the world, with an 
estimated 989,600 new cases [1]. GC occurrence varies globally and is more prevalent in 
East Asia (extremely high in South Korea, Japan and China) and South America 
(Figure1). With 72% of all new cases occurring in male patients, the incidence rate is 
twice as high in males as in females. Gastric cancer has a high mortality rate and is the 
second leading cause of cancer death worldwide, accounting for over 700,000 deaths 
annually [1]. In Singapore, the incidence rate was ~ 22.3 per 100,000 in 2002, with a 
mortality rate of 17.8 per 100,000 [5]. Despite the steady decline of gastric cancer 
incidence rates over the 30 years (Figure 1B) presumably due to  the diet changes, 
improved sanitation and increased screening (especially in Japan), the absolute incidence 
rate has risen because of the aging of the world population.  
1.2.2 Diagnosis 
Early stage gastric cancer is often asymptomatic and thus can seldom be detected. 
Therefore, in countries with high incidence rates of gastric cancer such as Japan, mass 
endoscopic screening programs are conducted for early diagnosis and treatment [6]. 
Usually, a double-contrast barium x-ray followed  by an upper endoscopy (EGD) is the 
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main procedure to diagnose gastric cancer on patients who present with the symptoms 
such as weight loss, abdominal pain, nausea and vomiting or those with multiple risk 
factors [7]. A biopsy is required if any abnormality is seen by EGD. Further tests, 
including endoscopic ultrasound, computed tomography scan and positron emission 
tomography scan are necessary after the initial diagnosis of gastric cancer to determine 
treatment options.   
 
FIGURE 1. Epidemiology of gastric cancer.  
(A) Age adjusted incidence rates of gastric cancer per 100,000 in 2008. (B)  Trends in 
age adjusted incidence rate of stomach cancer per 100,000 men in selected countries. 
(Reproduced from Globocan 2008. http://globocan.iarc.fr/) 
 
Tumor stage is an important indicator for both diagnosis and treatment of gastric 
cancer. There are two major staging systems for gastric cancer: the Japanese 
Classification of Gastric Cancer (JCGC) [8] and the International Union Against Cancer's 
tumor-node-metastasis (TNM) system [9]. The 5-year survival rates for gastric cancer 
vary significantly for different stages. The 5-year survival rate for stage I can reach up to 




Two main systems of histological classification are widely used: the Laurén 
classification and the WHO classification. 
The Laurén system classifies according to the pathological criteria and consists of 
two main types: the intestinal type and the diffuse type [11]. Intestinal type gastric tumors 
form irregular tubular or papillary structures and are normally well differentiated. Diffuse 
type gastric tumors have structures that are inconspicuous, may have signet-ring cells, 
and are undifferentiated or poorly differentiated. Adenocarcinomas of this type tend to 
aggressively invade the gastric wall. The intestinal type carcinomas frequently occur in 
old men while the diffuse type is more prevalent in young women [12]. A third type, 
termed "mixed", contains both intestinal and diffuse histological features [13]. The mixed 
type is more aggressive and tends to have larger sized tumors, deeper invasion, and more 
common lymph node metastasis compared to the other two types [12].  
The Laurén classification is roughly comparable with the WHO classification 
[14]. The WHO classification classifies gastric cancer into four main categories: Tubular, 
papillary, mucinous, and poorly cohesive based on the descriptive criteria [15]. The 
papillary, tubular and mucinous subtypes of gastric cancer are usually classified as 
intestinal according to the Laurén system, while poorly cohesive tumors are always 
classified as diffuse in the Laurén system. 
Genetic and epigenetic alterations vary significantly between intestinal and 
diffuse gastric cancer  [16], which has led to the hypothesis that the two subtypes have 
different etiologies. The “Correa Model” [17] posits that an intestinal tumor progresses 
through a number of sequential steps, which usually start from the gastritis caused by H. 
pylori infection. Then it progresses subsequently from atrophic gastritis to carcinoma. 
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However, diffuse gastric cancer is not included in this model, and no premalignant lesion 
is known. Thus this model suggests that these two subtypes differ significantly in their 
molecular pathways of tumorigenesis. 
1.2.4 Treatment 
Surgery is the most common treatment for all stages of gastric cancer. The basic 
goal is to remove all cancer and a margin of normal tissue, but the effects depend on the 
extent of invasion and the location of the tumor.  
Besides surgery, radiation therapy and chemotherapy are often applied to treat 
gastric cancer. Radiation therapy kills cancer cells by high-energy x-rays and 
chemotherapy uses drugs to stop the growth and division of cancer cells. Most 
chemotherapy treatments apply the combination of at least two drugs, such as 
fluorouracil (5-FU, Adrucil) and cisplatin (Platinol) [18, 19]. Our recent study [20] 
identified three robust subtypes in gastric tumors: "invasive", "proliferative" and 
"metabolic" based on gene expression profiling, and we found that metabolic-subtype 
tumors were preferentially sensitive to 5-FU treatment, while invasive-subtype may be 
more sensitive to PI3K/AKT/mTOR pathway inhibitors. Another study found that 
patients with higher EGFR expression benefit from the chemotherapy using the 
combination of 5-FU and cisplatin. [21].  
No standard of care has been established for gastric cancer yet, because gastric 
cancer is a heterogeneous disease and the relative benefits of drugs are unclear [22]. 
However, the development of targeted therapy casts light on the treatment of gastric 
cancer. Targeted therapy interferes with specific molecules that are involved in tumor 
growth and progression in order to inhibit the growth of cancer. It can improve clinical 
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outcomes and generally does not have the same types of severe side effects as standard 
chemotherapy. The recent ToGA (Trastuzumab for Gastric Cancer) trial has shown that 
Trastuzumab,  a HER2 inhibitor, when combined with chemotherapy, improved the 
overall survival of patients with HER2-positive gastric tumors [22].  We have also 
reported that FGFR2-amplified tumors show sensitivity to dovitinib, a FGFR/VEGFR 
targeting agent [23]. 
1.2.5 Etiology 
There is strong evidence that environmental factors, which presumably lead to 
somatic genetic and epigenetic alterations, play a major role in gastric carcinogenesis. In 
some cases, there are also known inherited genetic risk factors for gastric 
adenocarcinoma. Chronic inflammation, exposure to carcinogens and genetic 
susceptibility significantly increase the risk of gastric cancer [24, 25].  
Helicobacter Pylori Infection 
H. pylori, a bacterium that colonizes the gastric epithelium, is the strongest known 
risk factor for gastric cancer, especially cancers in the lower part of the stomach. H. 
pylori is estimated to contribute ~75% of the risk of gastric cancer [26]. H. pylori 
carcinogenesis includes several mechanisms. H. pylori infection may lead to chronic 
gastritis, gastric atrophy and intestinal metaplasia [27-31], which constitute progression 
towards intestinal-type gastric cancer [17].  Strain-specific bacterial virulence factors, 
such as the vacuolating cytotoxin VacA and CagA of the cag pathogenicity island (cag-
PAI), also play a key role in disease outcome [32, 33].  
Diet, Smoking and Alcohol 
8 
 
Evidence has shown that consumption of salted meat and fish, smoked foods and 
N-nitroso compounds, together with a low intake of fresh fruits and vegetables, increases 
the risk of developing gastric cancer [34-36]. Animal experiments indicated that ingestion 
of salt can cause gastritis and enhance pathogenic response to H. pylori infection [37]. A 
questionnaire study on 2112 Welsh men with 13.8 years follow-up revealed a significant 
decrease in cancer risk by the consumption of fresh fruits and vegetables [38]. The same 
result was also observed in a large scale cohort study of 265,118 adults in Japan from 
1966 to 1982.  
In addition, studies have shown that gastric cancer is associated with smoking and 
alcohol consumption. The study of 19,657 men from 1990 to 1999 revealed that smoking 
increased the risk of the differentiated type gastric cancer [39]. Another study between 
1974 to 1992 on the cohort of 32,906 people showed that the relationship of gastric 
cancer with smoking is dose-dependent [40]. Cigarette smoke promotes gastric tumor 
growth [41] and is a more pronounced risk factor in cardia gastric cancer (gastric cancer 
in the upper part of the stomach). Another case-control study from Russian based on 448 
cases and 610 controls indicated the relationship between hard liquor drinking and cardia 
gastric cancer in men [42]. 
Genetic Susceptibility 
Several known inherited factors attribute to risk for gastric cancer, including 
inherited cancer predisposition syndromes, genetic polymorphisms, and germline 
mutations. 
 Individuals with inherited cancer predisposition syndromes such as Lynch 
syndrome, Li-Fraumeni syndrome, and hereditary diffuse gastric cancer (HDGC) 
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syndrome, have a higher risk of developing gastric cancer [43, 44].  Lynch syndrome, 
also known as hereditary non-polyposis colorectal cancer, is an autosomal dominant 
inherited medical condition that has an increased risk of gastric cancer as well as other 
cancers. Lynch syndrome is caused by the defects in DNA mismatch repair genes such as 
MSH2, MLH1, MSH6, and MLH3, which lead to microsatellite instability [45-48]. Li-
Fraumeni syndrome is a hereditary disorder caused by germline mutations in TP53 [49]. 
It is characterized by first appearance of cancer at a young age and recurrence over the 
whole life span. HDGC syndrome is characterized by susceptibility for diffuse gastric 
cancer and the majority of HDGC patients possess germline mutation of E-cadherin 
(CDH1) [50-53]. 
Germline mutations of certain genes were also observed in gastric cancer. β-
catenin and APC mutations were frequently observed in intestinal type gastric cancer [54, 
55]. In addition, BRCA2 germline mutations were found in 21% of HDGC patients [56].  
Polymorphisms in the human interleukin (IL)-I beta gene and IL-I receptor 
antagonist gene are associated with an increased risk of gastric cancer due to H. pylori 
infection [57], and the pro-inflammatory polymorphisms of cytokines TNF-α and IL-10 
also altered the risk of noncardia gastric cancer (gastric cancer in all other areas of the 
stomach other than the top portion) [58]. In addition,  recent genome-wide association 
study of gastric adenocarcinoma tested over 500,000 single nucleotide polymorphisms 
(SNPs) for association with gastric cancer in 2,240 cases and reported that polymorphism 
of a SNP in PLCE1 at 10q23 showed significant relationship with the susceptibility of 
cardia gastric cancer [59].  
1.2.6 Molecular Pathogenesis 
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Gastric cancer is triggered by multiple somatic alterations, genetic or epigenetic, 
involving a number of oncogenes, tumor-suppressor genes, and DNA-repair genes. These 
prominent aberrations include somatic mutations, genomic copy number alterations, LOH, 
and DNA methylation, histone acetylation/methylation. Accumulated genomic damage 
eventually affects different cellular pathways and causes them to sustain proliferative 
signaling, evade growth suppressors, resist cell death, enable replicative immortality, 
induce angiogenesis, and activate invasion and metastasis [60].   














FIGURE 2. The TP53 pathway.  
Reproduced from [61]. 
 
TP53 Pathway 
Frequent LOH and mutations in TP53 are well-known mechanisms of 
carcinogenesis [62-65]. The TP53 tumor suppressor gene plays a vital role in the 
response to environmental and intracellular stresses.   
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In normal cells, MDM2, an E3 ubiquitin ligase, forms a complex with TP53 to 
regulate its degradation. Inhibition of this process causes the activation and accumulation 
of TP53. The TP53 gene then directly regulates the downstream genes to modulate 
growth arrest (p21), apoptosis (BAX), DNA repair (GADD45) or protein degradation 
(MDM2) (Fig 3).  
NF-κB Pathway 
Inflammation caused by H. pylori infection is strongly associated with gastric 
carcinogenesis, and the activation of NF-κB is a critical regulator of genes involved in 
immune and inflammatory responses [66]. The general pathway is described in Fig 4. 
Without stimulation, NF-κB dimers interact with the inhibitors of NF-κB (IκBs) and 
remain inactive in the cytoplasm [66].  The activation and translocation of NF-κB into 
the nucleus is controlled by the degradation of IκBs. IκBs are phosphorylated by the I
κB kinases (IKKs) and undergo proteasome-dependent degradation in response to a 
variety of extracellular stimuli following H. pylori infection [67]. H. pylori delivers 
cytotoxin-associated gene A (CagA), a cag-PAI encoded protein, into the epithelial cell 
cytosol, which is phosphorylated and binds to tyrosine phosphatase to trigger the NF-κB 
activation cascade. In addition, the activation of the NF-κB pathway is triggered by 
various pro-inflammatory cytokines such as IL-1β and TNF-α. Lipopolysacharide 
(LPS), which target spanning-membrane receptors IL-1R, TNFR and TLR4 (Toll-like 
receptor 4) respectively, is a major outer membrane component activated by the NF-κB 
pathway. In tumor cells, the activation of NF-κB has impaired regulation [68-70]. 
Subsequently, The activation of NF-κB induces inflammatory and tissue-repair genes 
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including MIP-2, MMP3, and VEGF and also increases the expression of ICAM-1, a cell 
adhesion molecule [67].  
Wnt Signaling Pathway 
Wnt signaling plays an important role in regulating cell proliferation and 
differentiation, and the pathway involves multiple interacting factors. Mutations in 
pathway-related genes including APC, β-catenin (CTNNB1) and AXIN, have been 
reported in gastric cancers [52, 71, 72]. In the absence of the extracellular Wnt ligands, 
the APC forms a complex with AXIN and GSK3β to phosphorylate β-catenin, an 
intracellular signaling molecule, which leads to the degradation of β-catenin. With the 
activation of Wnt, it binds to the cell-surface receptors of the Fizzled family and activates 
disheveled family protein (DSH), DSH then inhibits the activity of the APC-Axin-GSK3
β-β-catenin complex, resulting in the accumulation of β-catenin in the cytoplasm. β-
catenin binds to TCF reporters to activate Wnt target genes involved in cell cycle, 
apoptosis, cell growth and cell adhesion (Fig 5).  
1.2.6.2 Genetic and Epigenetic Alterations 
Gastric cancer is a complex disease and undergoes various somatic genetic and 
epigenetic alterations, including single nucleotide substitution, genomic copy number 

















FIGURE 3. NF-κB pathway activation induced by H. pylori infection.  














FIGURE 4. The canonical Wnt signaling pathway.  





Somatic mutations have long been studied in gastric cancer [52, 55, 75]. The 
initial studies of somatic mutations in primary gastric cancer focused on TP53, a well-
known tumor suppressor gene, and discovered a range of non-synonymous mutations that 
frequently occur in gastric cancer, especially in early-stage tumors [63, 64]. 
Subsequently, studies have revealed that somatic mutations in APC and β-catenin play 
key roles in tumor progression [52, 55]. KRAS, an important gene in the mitogen-
activated protein kinase (MAPK) cascade, is also frequently activated due to mutations in 
the caused progression of gastrointestinal malignancies [76, 77]. In addition, TTFI1, a 
candidate tumor-suppressor gene that provides a physical barrier at the gastric mucosa 
against various noxious agents, was found to lose its expression due to mutations [75]. 
The development of next-generation sequencing has vigorously boosted the 
genome-wide mutational analysis of gastric cancer with lower cost compared to 
previously available sequencing methods. Recent studies using exome-sequencing have 
reported several novel cancer-related genes that are frequently mutated in gastric cancer, 
including ARID1A and FAT4 [78, 79]. Somatic inactivation of these genes by mutations 
likely contributes to gastric tumorigenesis based on analysis in large series of tumors and 
based on experiments in cell lines. 
Copy Number and Gene Expression Alterations 
Genome-wide analyses of gastric cancer have revealed several regions of 
recurrent changes in DNA copy number, which indicate the possible location of 
oncogenes and tumor suppressor genes involved in gastric tumorigenesis. Copy number 
alterations such as recurrent genomic amplifications on chromosome arms 1p, 6p, 7q, 8p, 
11q, 16q, 17q, and 20q and deletions on chromosome arms 3p, 4q, 5q, 9p, 16p, 17p and 
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18q are common in gastric cancer [80-83]. Copy number changes are often accompanied 
by expression alterations of genes in the corresponding regions. Many gastric cancer-
related oncogenes are up-regulated by DNA amplification, including C-MET, K-SAM and 
ERBB2 [83-87]. In addition, gastric cancers sometimes show down-regulation of tumor-
suppressor genes (TSGs), including RUNX3 and FHIT, by copy number loss, leading to 
the loss of functions of these two tumor suppressor genes [88, 89]. 
The global gene expression profiles of gastric cancer have provided distinct gene 
signatures for diagnosis and treatment [20, 90-92]. A diversity of gene expression 
patterns in gastric cancer reflects variations in intrinsic properties of tumor and normal 
cells and variations in the cellular composition of gastric cancer [93]. Moreover, distinct 
gene expression profiles were also found between diffuse and intestinal gastric cancer 
[94]. Intestinal gastric tumors show overexpression of genes involved in cell proliferation, 
such as CDX1, MYO1A, MTP, and down-regulation of genes that are associated with 
epithelial differentiation. In contrast, in the diffuse type, genes encoding extracellular 
proteins are up-regulated, which is accompanied by the down-expression of e-cadherin 
(CDH1).  In addition, amplification of ERBB2 is especially common in intestinal gastric 
adenocarcinomas, while K-SAM and C-MET overexpression is more common in diffuse 
gastric tumors [95, 96].  
Microsatellite Instability (MSI)  
Microsatellites are short, repetitive DNA sequences that are widely and randomly 
distributed throughout the human genome. Microsatellite Instability (MSI) is 
characterized by novel-sized alleles detected in microsatellite sequences that are only in 
tumor tissues. MSI has been reported in many sporadic gastric cancers [63, 97, 98] and is 
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sometimes associated with germ-line mutations of the DNA mismatch repair (MMR) 
genes such as MSH2 and MLH1, which are involved in base-base MMR during DNA 
replication [99, 100]. Loss of MMR leads to an accumulation of DNA replication errors 
in cell proliferations, especially in short repetitive nucleotide sequences, which thus leads 
to MSI. Several studies have found that gastric cancers with high-frequency MSI (MSI-
H) show specific clinical phenotypes compared to low-frequency MSI (MSI-L) and 
microsatellite stable (MSS) tumors [101, 102]. MSI-H tumors tend to be of the intestinal 
subtype and have higher survival rates. MSI status also plays an important role in 
characterizing tumors and predicting prognosis, with MSI-L/MSS group showing better 
response to 5-FU treatment [103].  
Epigenetic Modifications 
Epigenetic modifications, such as DNA methylation and histone acetylation or 
methylation, are important alterations in gastric cancer. DNA hyper- and 
hypomethylation at CG dinucleotides (CpGs), were discovered to have a correlation with 
tumor suppressor gene silencing and oncogene overexpression, respectively [104, 105], 
and hypermethylation of CpG islands (CGIs , regions of high CpG density)  in gene 
promoters is widely associated with transcriptional silencing in cancer [105]. Numerous 
studies have investigated the role of DNA methylation in gastric cancer development, 
identifying genes frequently hypermethylated in gastric tumors such as MLH1 and 
CDKN2A [55, 98, 106]. Methylation is also a common second hit to the CDH1 gene 
subsequent to the germ-line mutation of the first allele, which is a major cause for 
hereditary diffuse gastric cancer [107]. In eukaryotic cells, five different histone proteins 
exist, termed H1, H2A, H2B, H3 and H4. Certain histone modifications, such as 
17 
 
methylation, and acetylation can lead to the change of the structure of the chromatin, 
which may contribute to gene activation or silencing. Hypo-acetylation of histones H3 
and H4 in the p21 promoter region is frequently observed in gastric cancer [108]. While 
conducting global acetylation analysis, the level of acetylated histone H4 is much lower 
in gastric cancers compared with that in non-neoplastic mucosa, which indicates a strong 
correlation between the reduced histone H4 acetylation and the tumor progression [109].  
1.2.7 Gastric Cancer Biomarkers 
Gastric cancer is a heterogeneous disease comprising multiple intrinsic subtypes 
and is naturally resistant to many anticancer drugs. The discoveries of biomarkers to this 
cancer may make personalized treatment possible, which may reduce the mortality and 
improve the effectiveness of therapies. Tan et al used gene expression profiles to reveal 
the distinct biological properties of gastric cancer groups, and found two intrinsic 
genomic subtypes (G-INT and G-DIF) that had different response to 5-FU and oxaliplatin 
treatment [110]. Another recent study showed three robust subtypes ("invasive", 
"proliferative" and "metabolic") from the study of two large gastric cancer cohorts and 
discussed their differences in therapeutic vulnerabilities [20].  In addition, a 
comprehensive bench-to-bedside model for personalized treatment of gastric cancer 
considering both genomic markers and environmental effects has been developed and 
proposed [111]. Patients can be classified into low and high metastatic risk groups 
according to prognostic gene signatures and low-risk patients can avoid chemotherapy 
toxicity by applying surgery alone. Although gastric cancer treatment remains a major 
challenge, an increasing number of studies reveals that new, robust biomarkers may 
significantly improve the survival rates of patients. 
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1.3 Loss of Heterozygosity 
1.3.1 General Introduction to LOH 
Loss of heterozygosity (LOH) is a genetic abnormality that causes the loss of one 
normal allele of a specific gene when the other allele has already been mutated. In other 
words, LOH is a constitutional genotype change from heterozygous to homozygous in 
somatic cells. According to Knudson's "two hit" hypothesis of tumorigenesis raised in 
1971 [4], the first hit is usually a point mutation that inactivates one copy of a tumor 
suppressor gene (TSG), and individuals will not develop cancer at this point. Instead, 
they develop cancer only when the second hit occurs, which causes the loss of the 
remaining functional TSG allele. LOH occurs at a higher frequency than single 
nucleotide substitutions and the still-intact copy of the gene is far more likely to be lost 
through LOH than by a second point mutation. Hence, LOH is a common second hit in 
carcinogenesis. As a result, detection of LOH has been widely used to identify genomic 
regions that harbor TSGs and to characterize different tumor types, pathological stages 
and progression [112, 113]. 
LOH may occur due to non-disjunction, mitotic recombination, deletion, 
chromosome non-disjunction and reduplication, or gene conversion (Fig 6). Regions 
subject to hemizygous loss of DNA copy number exhibit LOH, but the converse is not 
always true. LOH without copy number changes, or Copy Number Neutral Loss of 
Heterozygosity (CNNLOH), is caused by duplication of the chromosome containing the 
mutated allele and loss of the chromosome containing the normal allele. It is also 























FIGURE 5. Different genetic mechanisms that cause LOH. 
(White circle: normal allele, black circle: mutated allele.) 
 
1.3.2 LOH and TSGs in Cancers 
LOH is a common genetic alteration that is observed in various solid tumors. 
LOH was found on chromosome 5 in 20% of the colorectal cancers [114]. Subsequent 
studies showed that the mutational inactivation of TSGs caused by LOH predominates in 
colorectal cancer, including LOH of alleles at chromosomal regions 5q (APC), 17p (TP53) 
and 18q [115]. A significant level of LOH has been found at several sites in ovarian 
cancer, including 3p, 6q, 11p, 17q [116-118]. LOH occurs most frequently on 
chromosomes 3p, 13q and 17p in lung cancer, likely representing the inactivation of key 
tumor suppressor genes including FHIT, TP53 and RB [119-121]. In such cancers as lung, 
non-disjunction 
 
mitotic recombination chromosome non-
disjunction and 
reduplication of the 




ovarian, and colorectal cancers, LOH is found at an early stage of tumor progression 
[122-124].  
These findings, accompanied by the discoveries of gene mutations in region of 
LOH, reveal many TSGs. Inactivation of TP53 due to loss of heterozygosity has been 
demonstrated in a variety of cancers [125-127]. TP53 plays a key role in apoptosis, 
genomic stability, and inhibition of angiogenesis. The p16 gene encodes a protein that 
can inhibit the ability of CDK4 and CDK6 to phosphorylate the retinoblastoma protein 
and the inactivation of this protein may lead to uncontrolled cell cycling and growth. The 
region containing CDKN2A undergoes frequent allelic loss in multiple cancers [128-131]. 
Several well-studied known TSGs are summarized in table 1.  
1.3.3 LOH in Gastric Cancer 
LOH plays an important role in gastric tumorigenesis due to its ability to 
inactivate TSGs. LOH can be detected in up to 80% of gastric tumors, and LOH 
frequency increases during tumor progression [132]. Many studies have been conducted 
to comprehensively analyze LOH in gastric cancer and have revealed several 
chromosome arms that frequently undergo LOH, including 1q, 3p, 4p, 5q, 7p, 8p, 9p, 
11q, 12q, 13q, 17p, 18q, 21q, and 22q [133-135]. LOH analysis also identified several 
arms and regions along the genome that contain TSGs important in gastric tumorigenesis, 
such as 17p (TP53) [134], 5q (APC), and 18q (DCC and SMAD4). Table 2 summarizes 
the chromosomal regions that frequently undergo LOH in gastric cancer and the tumor 
suppressor genes (if known) that are targeted by LOH events in these regions. 




























CDKN2A (p16) 9p21 many types CDK inhibitor [128-131] 
PTEN 10q23.3 
glioblastoma; prostate, 
breast, and thyroid 
carcinomas 








control of E2Fs 
[146-149] 
CDH1 16q22.1 invasive cancers cell-cell adhesion [150, 151] 
TP53 17p13.1 






TABLE 2. Regions that undergo frequent LOH in gastric cancer. 
Chromoso
mal regions 
TSGs Frequency References 
1q  50%-67% [134, 152] 
3p FHIT 32.4% [153] 
5q APC, MCC 34%-60% [134, 154] 
7q TES 32%-43% [154-156] 
8p  44% [157] 
9p  36.4% [158] 
10p KLF6 53% [159] 
12q  55% [152] 
13q  38.1%-41% [158, 160] 
17p TP53 37.5%-68% [134, 156, 158, 161] 
18q SMAD4, DCC, BCL2 29%-61% [158, 161-163] 
21q  40%-43% [154, 156] 
 
1.4 Genome-Wide SNP Array Application on CNA and LOH Analysis 
1.4.1 Genome-wide SNP Array 
Traditional methods to study CAN and LOH such as restriction fragment length 
polymorphism (RFLP), molecular cytogenetic analysis, florescence in situ hybridization 
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(FISH) and microsatellite analysis, require a lot of time and effort. The instability of the 
markers and the difficulty of automating PCR based analysis make their usage for 
genome-wide studies unpractical. 
The invention of microarrays makes possible the high-throughput analysis of 
CNA and LOH on a genome-wide scale. Array-based comparative genomic hybridization 
(aCGH) is a technology with probes detecting total copy number of genomic sites. 
Because aCGH is unable to detect allelic states of SNPs, it is only applicable to analyze 
genome-wide DNA CNAs [164-166]. In addition, the number of probes and thus the 
genomic resolution in this older array technology was lower than that of the chips now 
available [167]. 
The development of single nucleotide polymorphism (SNP) arrays provides a 
major advance. SNP arrays offer the advantage of providing high resolution genotype 
information in addition to copy number variation information in a single experiment with 
a very high density of genomic coverage. With genotype information, it is possible not 
only to determine the de novo CNA in patients, but also to decide the origins of 
chromosomes, check for sample mix-up, and study copy number neutral genomic 
variation such as uniparental disomy and copy number neutral loss of heterozygosity. 
Advances in computational methodology have been critical in facilitating application of 
this technology to molecular genetics. 
Affymetrix and Illumina are two major manufacturers of SNP array platforms that 
are widely used. The differences between them are the underlying technologies. 
Affymetrix GeneChip assays are based on the hybridization of genomic DNA to assays. 
Oligonucleotides of probes are printed directly on the chips. The probes are 25-mer 
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sequences targeting both alleles of the SNPs. A DNA segment with complete 
complementary sequences will be hybridized to the chip and bind to the specific probe 
more efficiently than a probe with a mismatch, which is represented by a higher 
fluorescence signal that can be detected.  However, Illumina Infinium II assays use a 
single base extension method to obtain the allelic information for SNPs. Beads with DNA 
probes sticking out of them are randomly deposited into microwells on a substrate. Each 
bead contains a 29-base unique sequence to allow the identification of probes. The probe 
sequences are 50 bases long SNP locus-specific primers and are complementary to the 
sequences adjacent to the SNP sites. After DNA fragmentation and hybridization to 
probes, they are extended with hapten-labelled nucleotides and the incorporated 
nucleotides are detected by fluorescence-labelled antibodies for further analysis. Because 
of these differences, data processing procedures of the platforms from these two 
manufacturers are slightly diversified.  Our study only uses Affymetrix SNP 6.0 arrays 
and the details will be described.  
The Affymetrix Genome-Wide Human SNP Array 6.0 allows us to look 
simultaneously at more than 1.8 million probe sites on a single array with an inter-marker 
distance of 696 base pairs [168]. The chip includes 906,600 SNP probes and 946,000 
non-polymorphic probes, with the latter targeting non-SNP loci. For each locus, the chip 
contains three or four replicated pairs of 25-nt perfect-match (PM) probes quantifying the 
amount of DNA target to optimize the accuracy of estimation. The two alleles of a SNP 
are arbitrarily labeled as "allele A" and "allele B". Therefore, the genotype of a SNP from 
a diploid sample is typically AA, AB or BB. 
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The basic flow of processing for SNP 6.0 arrays is described in Fig 8. In short, 
500 ng of total genomic DNA is digested with Nsp I and Sty I restriction enzymes. 
Fragments from restriction enzyme digestion, regardless of size, are then ligated to 
universal adaptors. A generic PCR primer that recognizes the adaptor sequence is used to 
amplify these adaptor-ligated DNA fragments, and PCR products of 200 to 1,100 bp in 
size range are preferred by PCR conditions. These PCR amplified products are combined 
and purified, and then they are fragmented, labeled, and hybridized to a SNP 6.0 Array 












FIGURE 6. The overview of the flow of a Affymetrix Genomewide SNP array. 
Reproduced from www.affymetrix.com. 
 
Each allele of a SNP has three or four replicated perfect match probes that are 
completely complementary to the sequences of the allele. These probes are printed 
directly on the chip. As shown in Figure 7, six rectangles comprises the probes for a SNP, 
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with the top three target one allele and the bottom three target the other allele, 
respectively. If there are equal amounts of DNA with each genotype, the post-
hybridization intensities of the top three rectangles will be similar to those of the bottom 
four rectangles. If only one allele is present in the DNA, e.g. the allele complementary to 
the top rectangles, then the top three rectangles will be much brighter than the bottom 
four rectangles. If there is allelic imbalance, which can occur in cancer, then the two 
alleles might be present, for example, in a ratio of 2:1.  In this case, if the more abundant 
allele is detected by the top rectangles, these will be approximately twice as bright as the 
bottom rectangles. Therefore, from the signal intensities of the rectangles detected, we 
can infer the allele specific copy numbers. 
After hybridization, each SNP array slide is scanned and the array probe signal 
intensities are obtained. A number of preprocessing steps are required to convert raw 
intensity measurements into biological inferences, and these steps can significantly 
influence the quality of the ultimate measurements. The underlying principle is that the 
signal intensities mainly depend on the amount of target DNA in the sample. The 
intensities of the fluorescence signals may be affected by various systematic variations 
such as the array manufacturing process and the affinity between targets and probes. To 
accurately estimate the true copy number of each allele, the raw data need to be 
normalized considering these systematic errors. Many algorithms have been developed to 
normalize the raw intensities [169-171],  such as quantile normalization [172] and Copy-
number estimation using Robust Multichip Analysis (CRMA) v2 [173]. These algorithms 
take the raw intensity image of SNP arrays as inputs and derive the signal intensities for 
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the A and B alleles through several normalization steps. The former algorithm is applied 
in analyzing multiple arrays, while the latter one is suitable for single array processing. 
Genotyping is also crucial to obtain information out of the raw intensities. For the 
early series of SNP data, the partitioning around medoids (PAM)-based algorithm [174] 
and a dynamic model algorithm [175] are utilized. With the evolution of the platforms, 
more and more new algorithms have been developed and are proven more accurate in 
genotyping the SNP arrays, such as BRLMM-P [176],which models the log-transformed 
intensities as a stochastic function, and Birdseed [177], which uses an expectation-
maximization (EM) procedure to fit the signals from the test samples to a two-
dimensional Gaussian mixture model with a priori. 
The preprocessed data are further analyzed for various applications such as 
genome-wide association studies, copy number and LOH analysis. The latter two 
analyses will be described in the next part. 
1.4.2 Application of SNP Arrays on Copy Number and LOH Analysis 
The SNP array offers the ability to define CNA and LOH in a tumor 
simultaneously and is a powerful platform for oncogene and TSG discoveries. Genome-
wide LOH analysis using SNP arrays is typically performed by comparison of tumor and 
adjacent normal genomic DNA from the same individual. LOH can be discovered by a 
change from a heterozygous state in the normal sample to a homozygous state in the 
tumor sample. If a matched normal is unavailable, several algorithms are also available to 
analyze the SNP array using pooled references [178, 179]. 
Many free or commercial tools have been developed for the SNP array data 
analysis, including Affymetrix Genotyping Console (GTC), Affymetrix Power Tools 
27 
 
(APT), Nexus (BioDiscovery, http://www.biodiscovery.com/software/nexus-copy-
number/), Copy Number Analyser for Genechip (CNAG) [179], dchip [180], PennCNV 
[163], PICNIC [181], QuantiSNP [182], Genome Alteration Print (GAP) [183], Parent-
Specific Copy Number (PSCN) [184], Tumor Aberration Prediction Suite (TAPs) [185] 
and Allele-Specific Copy Number analysis of Tumors (ASCAT) [186]. Details will be 
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We evaluated several publicly available software packages for analysis of copy 
number analysis (CNA) and loss of heterozygosity (LOH). We evaluated their 
performance on a previously published data set [185] that consists of a dilution series of 
cancer-cell-line DNA mixed with matched germ-line DNA.  The dilution series was 
assayed on Affymetrix SNP 6.0 arrays. Here we describe, compare, and evaluate the 
performance of the algorithms utilized by these methods in each step of analyzing SNP 
array data. ASCAT and CNAG outperformed the other methods in inference of CNA and 





CNA and LOH are important types of genetic alteration in cancers [187], and 
characterization of these alterations plays a key role in both diagnosis and drug 
development. Single nucleotide polymorphism (SNP) arrays provide a genome-wide high 
resolution view of these alterations. Several high-throughput studies have applied SNP 
arrays to characterize CNA and LOH in various cancers [188-191]. The power of SNP 
arrays for this application depends on sophisticated computational methods.  
Affymetrix Genome-Wide Human SNP Array 6.0 arrays interrogate > 1.8 million 
genomic sites, including 906,600 SNPs and 946,000 non-polymorphic sites, at the latter 
of which it assesses copy number. For this array design, average inter-marker distance is 
696 base pairs [168]. For each SNP site, the chip contains three or four overlapping pairs 
of 25-nt probes. Each probe is perfectly complementary to one of the two alleles at the 
SNP. The two alleles of a SNP are by convention labeled "allele A" and "allele B" 
regardless of the actual bases. Thus, each SNP probe is associated with either "allele A" 
or "allele B", and the genotype of a SNP is denoted AA, AB or BB. To estimate copy 
number and allelic imbalance at each SNP one uses two values: the log R ratio (LRR) and 
the B allele frequency (BAF). LRR is the log of the ratio of observed tumor probe 
intensities to reference normal intensities, and deviations of LRR from zero are evidence 
for CNA. BAF is the proportion of the B allele in the two-allele mixture. Deviations of 
BAF values from the expected 1:1 ratio at heterozygous sites constitutes allelic imbalance 
and indicates aberrant copy numbers of at least one of the two homologous chromosomes 
at that site. 
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Complications in estimation of CNA and LOH from LRR and BAF arise from 
several sources, including prominently (1) tumor aneuploidy and polyploidy and (2) 
admixture of DNA from non-malignant genomes. 
Tumor aneuploidy is the chromosomal instability that reflects the defects in 
mitotic segregation in cancer cells. The total amount of DNA in an aneuploid tumor 
sample can differ significantly from the diploid normal sample. Due to the restriction of 
the technique, the protocol for SNP arrays constrains the amount of DNA other than the 
number of cells to be the same for each assay. Therefore, a 2n segment in a triploid tumor 
sample will show smaller signal intensities compared to the same 2n segment in the 
diploid normal sample (LRR < 0), and without adjusting the ploidy state, the data will be 
similar as a hemizygous deleted segment in a diploid tumor sample. The reason is that the 
zero baseline of the LRR does not represent a normal diploid copy number but an average 
copy number of the tumor sample.  
The second problem in mining SNP array data arises from the admixture of non-
tumor cells in the tissue sample from which the DNA sample is extracted. The presence 
of a normal DNA dilutes the amplitude of the signal changes that reflect the genomic 
alterations in the tumor DNA. Thus, using  fixed thresholds to detect the copy number 
variations may fail due to this admixture of non-tumor DNA [192, 193], and considering 
the proportion of tumor DNA  increases the accuracy of copy number estimation [185, 
186]. 
The basic steps to analyze data generated by SNP arrays include: (1) 
normalization, (2) genotype calling, (3) LRR and BAF calculation, (4) segmentation, and 
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(5) CNV and LOH calls.  Figure 20 provides a comprehensive overview of the algorithms 
used by each tool for each step.  
Many free or commercial tools have been developed to estimate CNA and LOH 
from SNP array data, and they vary in their approaches to each of the basic steps.  
Several studies have evaluated and compared methods for CNA detection. 
Winchester et al. [194] compared the performance of five methods, including Birdsuite 
[177], CNAT (Copy Number Analysis Tool) [195], GADA (Genome Alteration 
Detection Analysis) [196], PennCNV [163], and QuantiSNP [182], on data generated by 
both Illumina 1M Duo and Affymetrix SNP 6.0 platforms. This study suggested the use 
of any two programs on a single dataset in order to utilize the advantages of each 
software package to improve sensitivity and specificity. This study also recommended the 
use of software that is specially designed for the platform to be used, such as QuantiSNP 
for Illumina SNP array data. In another study, Dellinger et al. [197] evaluated seven 
methods, including CBS (circular binary segmentation) [198], CNVFinder [199], 
cnvPartition [200], GLAD (Gain and Loss Analysis of DNA) [201], Nexus [202], 
PennCNV and QuantiSNP, in various processing steps on data generated by both the 
Illumina HumHap 550 and Affymetrix SNP 6.0 platforms. This study recommended 
determining the optimal parameters using a subset of samples with high-quality genotype 
call rates before analyzing the whole dataset. In yet another study, Eckel-Passow et al. 
[203] focused on comparing the locus-level copy number estimates generated by four 
different tools, including APT (Affymetrix Power Tools) [204], Aroma. Affymetrix [205], 
PennCNV and CRLMM (Corrected Robust Linear Model with Maximum Likelihood 
Distance) [206], on data from Affymetrix SNP 6.0 arrays. They found that PennCNV had 
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a better performance and a more user-friendly interface and detected CNAs with smaller 
bias and variability of locus-level copy number data. These studies all showed that 
various methods have diverse advantages and need to be carefully chosen to meet 
specific requirements.  
However, these studies only focused on CNA analysis and did not carry out any 
comparison of the performance of LOH analysis, even when the packages evaluated 
offered this capability. In addition, all these studies compared segmentation-based 
algorithms and HMM-based algorithms to identify CNAs, but the performance of 
recently developed pattern recognition algorithms have not been investigated. The 
differences between the types of algorithms will be discussed later. An additional 
limitation of these studies is that they are all based on unpaired analysis, despite the fact 
that paired analysis of CNA and LOH by comparing the tumor sample to its matched 
normal samples has been effective in avoiding the miscall of germ-line copy number 
polymorphisms. Therefore, the present study focuses on the performance of different 
methods that simultaneously carry out both CNA and LOH detection.  
Here, we evaluate eight programs, including GAP (Genome Alteration Print) 
[183], Birdsuite, PennCNV, CNAG (Copy Number Analyzer for GeneChip) [179], 
PICNIC (Predicting Integral Copy Numbers In Cancer) [207], paired PSCBS (Parent-
Specific Copy-numBer Segmentation) [208], TAPS (Tumor Aberration Prediction Suite) 
[185] and ASCAT (Allele-Specific Copy Number analysis of Tumors) [186]. Although 
some of the programs have been already evaluated, we assessed the performances of both 
CNA and LOH analysis by these programs. We apply each of these methods to data from 
a dilution series of a single tumor cell line (NCI-H1395) mixed with increasing 
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proportions of germ-line DNA from the same donor, as reported in [185]. Spectral 
karyotyping indicates that the cell is approximately triploid [209]. The dilutions were 
assayed on Affymetrix Genome-wide SNP 6.0 arrays, and a spectral karyotype of the 
tumor was available to provide information on copy number independent of the 
Affymetrix data. The analysis provides a detailed picture of the performance of these 




2.3 MATERIALS AND METHODS 
2.3.1 Lung Cancer Cell lines 
The Affymetrix Human Genome-wide SNP 6.0 data of lung cancer cell line NCI-
H1395 with different tumor content (100%, 70%, 50% and 30%) and its patient-matched 
blood cell line NCI-BL1395 were obtained as .CEL file from GEO accessions GSE29172 
and GSM645856 (www.ncbi.nlm.nih.gov/geo/). In the dilution series, DNA from normal 
blood cell line NCI-BL1395 was mixed with DNA from the lung cancer cell line NCI-
H1395, and the DNA ratio was adjusted to compensate for NCI-H1395 being nearly 
triploid, so the proportions of tumor DNA were 100%, 80%, 65%, and 42%.  
2.3.2 CNA and LOH Analysis 
CNAG 
CNA and LOH analysis was performed by CNAG (version 3.3.0.1 beta) using the 
default parameters.  Paired samples with their references are matched in the data 
extraction .We chose “non-allele-specific analysis” with self-reference only. CN gains, 
losses and LOH were defined according to the default.  
Birdsuite 
CNA and LOH analysis was performed by PennCNV according to the online 
instructions (http://www.broadinstitute.org/science/programs/medical-and-population-
genetics/birdsuite/birdsuite-manual). Affymetrix Power Tools were utilized for data 
normalization before Birdsuite analysis. Birdseed was used for SNP genotyping and 
Canary was applied to genotype the known CNPs. The default settings by Birdsuite were 




CNA and LOH analysis was performed by GAP according to the online 
instructions and default settings (http://bioinfo-out.curie.fr/projects/snp_gap/). Allelic 
difference data were output from Affymetrix Genotyping Console 4.0 and were directly 
utilized by GAP as the inputs.  
PennCNV 
CNA and LOH analysis was performed by PennCNV according to the online 
instructions 
(http://www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.html). Quantile 
normalization and birdseed-v2 calling algorithm were used by Affymetrix Power Tools to 
generate the signal intensities and genotyping calls from raw CEL files. Allele-specific 
signals were then extracted to calculate LRR and BAF values. Copy number variation 
and LOH were calculated based on the Hidden Markov Model (HMM). 
PICNIC 
CNA and LOH analysis was performed by PICNIC according to the online 
manual 
(ftp://ftp.sanger.ac.uk/pub/cancer/picnic_software/picnic_src/PICNIC_implementation_g
uide.pdf). Matlab is used to execute the program. In general, we applied the default 
settings of PICNIC to normalized the raw signal intensities and generate contamination 
fraction and ploidy estimations. Then such information was the premise to infer CNA and 
LOH by HMM. 
ASCAT 
CNA and LOH analysis was performed by ASCAT. We preprocessed the raw 
SNP 6.0 array fluorescence signal with CRMA v2 and TumorBoost to get the normalized 
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LRR and BAF data. Then we applied ASCAT to generate allele-specific copy numbers 
from the pre-processed data. We used the following parameter settings: median 
smoothing; minimum segment length (kmin) =100SNPs; LRR compaction factor (γ) 
=0.5. In addition, we modified ASCAT to use a new parameter, α, which represents a 
BAF compaction factor analogous to the LRR compaction factor γ. We used α=0.6 for 
our analysis of Affymetrix SNP 6.0 arrays. We also modified the procedure whereby 
ASCAT’s segmentation algorithm determines whether there is allelic imbalance at a 
particular segment. All the programs are written in R. 
TAPS 
CNA and LOH analysis was performed by TAPS. We used CRMA v2 to 
preprocess the raw data, which is the same as described in ASCAT preprocessing. 
Segmentation of LRR is conducted by CBS. TAPS were then performed using the default 
settings.  
Paired-PSCBS 
CNA and LOH analysis was performed by paired-PSCBS according to the online 
instructions (http://www.aroma-project.org/vignettes/PairedPSCBS-lowlevel ). We used 
CRMA v2 to preprocess the raw data, which is the same as described in ASCAT 
preprocessing. The R package “Paired PSCBS” was utilized to run the programs. LOH 
was inferred by the LOH calling algorithm integrated into the package. We calculated the 
standard deviations by comparing the observed LRR to the estimated LRR. We also 
calculated the median estimated LRR, and the positive value of the median estimated 
LRR was set as the arbitrary sample-adaptive threshold for CN gains and the negative 
value was the threshold for CN losses.  
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2.4 RESULTS AND DISCUSSION 
Using the dilution series data generated from the lung cancer cell line NCI-H1395 
and its matched blood cell line NCI-BL1395 from [185], as described above, we 
evaluated the performance of eight programs commonly used for analyzing CNA and 
LOH. These tools apply various algorithms, as shown in Figure 20. A summarization of 
the features of these tools is also presented in Tables 10 and 11.  
2.4.1 Data Pre-processing 
The intensities of the fluorescence signals obtained by scanning the image of the 
chips are affected by various factors including both biological and non-biological 
variation. Several preprocessing steps are required to convert raw intensity measurements 
into biological inferences, and these steps can significantly influence the qualities of the 
ultimate inferences. Several preprocessing algorithms have been proposed to reduce 
unwanted non-biological variability and obtain the accurate CN information for each 
allele.  
GAP utilizes the CN5 algorithm [210], which is implemented on the Affymetrix 
Genotyping Console (GTC) to normalize signal intensities and estimate raw CNs. CN5 
applies adaptive background correction to address issues of optical background noise, the 
effects of non-specific hybridization, to probe-specific variation in intensity. To 
normalize across arrays, it uses sketch quantile normalization as the across-array 
normalization algorithm to address the effects of non-biological variation due to chip 
manufacturing and experimental procedures. Quantile normalization is a scaling based 
algorithm that makes use of a baseline array (usually with the highest genotype calls). 
The algorithm assumes that the distribution of signal intensity will not change and tries to 
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make the test array distribution and the baseline array distribution identical in statistical 
properties.  
Birdsuite and PennCNV employ Affymetrix Power Tools (APT) for 
preprocessing. APT uses RMA (Robust Multi-array Analysis) for background correction, 
sketch quantile normalization for inter-array variation removal, and PLIER (Probe 
Logarithmic Intensity ERror) for probe intensity summarization.  
PICNIC [207] first constructs a training group in the preprocessing step with 461 
normal samples from the Affymetrix SNP 6.0 array. It then applies a Bayesian approach 
to fit the allelic signal intensities of the tumor sample to the three clusters observed in the 
training group and uses the maximum posterior estimation to obtain normalized allele-
specific signals that map the three clusters. During this process, aneuploidy samples are 
automatically adjusted. It also estimates parameters required for segmentation, including 
tumor content and tumor ploidy.  
GAP, Birdsuite, PennCNV, and PICNIC all normalize the signal intensities of the 
tumor samples to pooled reference samples. The former three methods use the 270 
HapMap samples  from the International HapMap Project [211] and PICNIC uses the 461 
normal samples in the training group from [207].  Normalization strategies based on a 
pooled reference sample do not in practice distinguish somatic copy number alterations 
from germ-line copy number variation, because the algorithms do not examine the non-
tumor reference samples for copy number variation. 
CNAG [179] corrects the raw signal intensities of a sample by compensating for 
varied enzyme-digested fragment lengths and for GC content. CNAG addresses the issue 
of aneuploidy by accepting from the user an indication of regions that are a-priori thought 
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to be diploid. In CNAG, a paired normal sample is used as the reference for the 
corresponding tumor sample.  
CRMA v2 (Copy–number estimation using Robust Multichip Analysis) [173] is a 
single-array method to remove chip background noise, crosstalk between alleles, the 
effects of probe sequence composition on the stability of hybridization, and effects due to 
the varying lengths of the restriction fragments that are hybridized to the probes (and that 
vary systematically from SNP to SNP). Unlike Birdsuite and PennCNV that utilize 
quantile normalization and process multiple samples together, CRMA v2 can process 
each array independently, and for the paired analysis, only the tumor sample with its 
matched normal sample are required. Thus, it is easy to apply CRMA v2 to new arrays as 
they are produced without having to reprocess the old arrays. ASCAT, paired PSCBS and 
TAPS all use CRMA v2 for preprocessing. 
2.4.2 Genotyping 
Genotyping is a crucial step in the analysis of SNP array data. Accurate 
genotyping helps to exclude non-informative SNPs (those that are homozygous in the 
normal sample). However, because of tumor aneuploidy and because DNA from solid 
tumors usually also contains DNA from non-malignant cells, genotyping SNPs in the 
tumor sample is a very different problem from, and much more difficult than, genotyping 
SNPs in non-malignant DNA.   
GAP uses BRLMM-P (Bayesian Robust Linear Model with Mahalanobis distance 
classifier) [176] conducted on GTC for genotyping. BRLMM-P first calculates the initial 
genotype for each SNP using the DM algorithm [212]. It then random selects a subset of 
non-monomorphic SNPs to estimate the prior information of cluster centers and variance-
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covariance matrices. Combining the initial genotypes and the prior information, the 
algorithm applied a Bayesian procedure to get the posterior estimation of the three cluster 
centers as well as the variance matrices. Finally, SNP genotypes are delineated based on 
the Mahalanobis distance between SNPs and the three cluster centers. 
Birdsuite and PennCNV rely on Birdseed v2 [177] for genotyping. Birdseed v2 
uses an expectation-maximization procedure to fit the signals from the test samples to a 
two-dimensional Gaussian mixture model with a priori estimation. PICNIC genotypes 
SNPs simply based on the three clusters generated in the preprocessing step, and these 
clusters have already been adjusted by the aneuploidy information it estimates.  
CNAG utilized the WGSA (whole-genome sampling analysis) algorithm [213]for 
genotyping in order to remove non-informative SNPs from further analysis. WGSA 
derives clusters of genotypes from a fix set of 108 non-malignant training samples. The 
algorithm then partitions around medoids of clusters
 
to get the genotype for each SNP. 
Only three genotypes are called: AA, AB and BB. 
ASCAT, paired PSCBS, PICNIC, and TAPS employ the “naive genotyping 
algorithm” [214] to identify informative SNPs. This algorithm simply calculates the two 
local minima of the empirical density of BAF data in the normal sample and it sets the 
threshold based on the normal BAFs to call the genotypes. 
2.4.3 LRR, BAF and Decrease in Heterozygosity 
All the programs that we evaluated rely on LRR and BAF as key values from 
which to infer tumor genomic copy number and LOH state at each SNP. LRR and BAF 
are calculated based on the normalized signal intensities of each SNPs. LRR can be used 
to estimate total copy number, while BAF quantifies the imbalance between two alleles. 
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SNP arrays provide both total and allele-specific signals at SNP loci and only 
total copy number estimates at non-polymorphic loci. LRR at locus j, denoted Rj, is 
defined as to increase the signal-to-noise ratio, and the normalized decrease in 
heterozygosity can be used by ASCAT, paired PSCBS, and TAPS. 
To assess the accuracy of the five preprocessing approaches (CN5, Quantile, 
CRMA v2, CNAG, and PICNIC), we compared the median LRR and the median absolute 
deviation (MAD) of LRR across all loci (both polymorphic and non-polymorphic) on 
chromosome 17 as calculated from data from the lung cancer cell line NCI-H1395 (Table 
12). The spectral karyotype of this cell line indicates that all of chromosome 17 is triploid 
[209]. We found that CRMA v2 produced the minimum MAD when compared to other 
preprocessing algorithms. The models used by CNAG and PICNIC can account for 
aneuploidy and polyploidy in the tumor in calculation of LRR, and they have done so in 
the case. As a consequence, they both estimated higher LRRs than the other three 
methods, which implicitly assume that the tumor samples are approximately diploid when 
calculating LRRs. Preprocessing algorithms that use paired normal samples as references 
(CRMA v2, CNAG, and PICNIC) obtained lower MADs than preprocessing algorithms 
using pooled normal references (CN5 and Quantile normalization).  
2.4.4 Segmentation 
The signal intensities that reflect copy numbers are noisy, and four of the eight 
tools that we evaluate (GAP, paired PSCBS, TAPS, ASCAT) smooth LRRs and BAFs by 
segmentation. Segmentation splits the genome into regions with equal copy numbers. 
Circular binary segmentation (CBS) [198] is the most widely used algorithm for LRR 
segmentation. Because both LRR and BAF may carry information regarding the location 
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of copy-number change-points, CBS is also sometimes used to segment BAF values 
(usually transformed to decrease in heterozygosity, ρ) to identify regions with allelic 
imbalance and LOH. CBS assumes that the changes in total copy number or allele-
specific copy number that underlie the changes in measured LRR or BAF are discrete and 
affect contiguous markers on the genome. In our tests of CBS we have found that it is 
sensitive to consecutive outliers and tends to segment noisy regions into small 
fragmentary pieces; we have been unable to correct this by adjusting the smoothing 
parameters available (data not shown). 
GAP determines the breakpoints of LRR and BAF separately using CBS. TAPS 
and paired PSCBS apply a two-step segmentation strategy: they first detect change-points 
from the LRRs alone, and then further improve the change-points with the decrease in 
heterozygosity (ρ) values. TAPS makes use of k-means clustering method to identify 
and remove segments with non-informative SNPs, while Paired PSCBS directly removes 
non-informative SNPs based on the naive genotype calls of paired normal samples.  
ASCAT segments using the ASPCF (Allele-Specific Piecewise Constant Fitting) 
algorithm [186], which simultaneously fits piecewise constant functions to the LRR and 
ρ’s. ASPCF includes a penalty term for creation of each segment, and the sensitivity and 
specificity of ASPCF is significantly affected by the value of this term.  
2.4.5 CNA and LOH Calls in Programs that Use HMMs 
Four of the approaches we studied (CNAG, Birdsuite, PennCNV and PICNIC) do 
not have a separate segmentation step, but rather directly apply discrete state hidden 
Markov models (HMM) to LRRs and possibly BAFs to infer CNA and LOH. The HMMs 
aim to determine unobserved underlying states from a sequence of observed data points. 
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For these applications, the underlying states are taken from pre-specified, finite sets of 
total copy numbers and allele-specific copy numbers. The HMMs may fail to detect 
tumor-specific copy number variants and LOH due to the heterogeneity of tumor samples, 
which appear as fractional copy number changes rather than integer copy number states. 
Previous comparison of these algorithms with other methods have shown a loss of ability 
to detect copy number changes and LOH when tumors are diluted with normal cells [192], 
as is usually the case for solid tumors obtained by biopsy or surgery.  
CNAG defines seven total-copy-number emission states (0-6 copies) and two 
LOH states (“present” or “absent”). PennCNV’s HMM has six emission states: loss of 
one copy, loss of two copies, normal state (diploid), normal state with LOH, single copy 
duplication or double copy duplication. However, PennCNV does not provide 
information in its output about the copy-neutral LOH state. Birdsuite considers only total 
copy numbers, and emits one state out of the five possible pre-defined copy number 
levels (0-5 copies); thus, Birdsuite cannot identify regions of LOH. PICNIC, on the other 
hand, considers allele-specific copy numbers, which allows it to identify regions of likely 
LOH. 
2.4.6 CNA and LOH Calls in Programs that Use Segmentation 
Four of the programs that we assessed (Paired PSCBS, GAP, TAPS, and ASCAT) 
have separate steps that segment LRR and BAF prior to inferring total and allele-specific 
copy numbers. Paired PSCBS calls CN gains and losses based on a sample-specific 
arbitrary threshold, which is the median estimated LRR plus or minus 0.25 standard 
deviations (of the segment, respectively). Segments with LRRs greater than the upper 
threshold are called CN gains and those LRRs below the lower threshold are CN losses.  
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GAP and TAPS employ clustering and pattern recognition to decide CN and LOH 
states. They create two-dimensional clusters based on LRR and a measure that captures 
BAF information, and then match these clusters to specific allele-specific copy numbers. 
Both methods address the problems of tumor aneuploidy and admixture of DNA from 
non-malignant cells. To capture BAF information, GAP uses a measure called allelic 
difference, which is the ratio of intensity differences between the each of the two alleles 
in the tumor and the reference. TAPS uses a measure called the allelic imbalance ratio, 
which is calculated as (B/(A + B)), where A and B are the normalized signal intensities of 
allele A and allele B. These two methods both utilize two-dimensional scatter plot with 
LRR by either allelic difference (GAP) or allelic imbalance ratio (TAPS) (Figure 21), and 
both scatter plots capture similar information. An advantage of these clustering-based 
approaches is that that they can detect heterogeneity of chromosomal aberrations within a 
tumor, that is, the situation in which there are different populations of cells with different 
genomics aberrations. However, the accuracy of theses algorithms is significantly 
affected by the number clusters present in the sample. If there are only a few clusters, 
these methods tend to associate clusters with incorrect allele-specific copy numbers. 
Therefore, GAP and TAPS accept manual input regarding tumor ploidy, which can 
ameliorate this problem. 
In estimating allele-specific copy numbers, ASCAT also estimates tumor ploidy 
and the proportion of non-malignant cells in the source of the DNA sample as parameters. 
ASCAT searches across possible values for average tumor ploidy and for possible 
proportions of non-tumor cells to find values that minimize the total distance between 
estimated allele-specific copy numbers and nearest nonnegative whole numbers. 
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Therefore, ASCAT is more robust in the face of tumor aneuploidy and low tumor content 
than other methods. However, because the ASCAT algorithm tends to rely heavily on 
BAF information, tumors with BAF values that are uniformly close to 0.5 often cannot be 
analyzed by ASCAT. ASCAT also generates a goodness-of-fit score for each identified 
chromosomal copy-number aberration.  This score indicates ASCAT’s confidence in the 
estimated allele-specific copy numbers. ASCAT often cannot estimate allele-specific 
copy numbers from data with very noisy LRR or from samples with extremely low tumor 
content.  
2.4.7. Evaluation and Comparison of Eight Programs in Data from a Dilution 
Series 
We investigated how well the eight programs delineated CNA and LOH across 
the genome as the proportion of non-malignant DNA increases (Figure 22). Birdsuite, 
PennCNV and GAP detected the fewest CN gains and GAP found the fewest regions of 
LOH even in the pure tumor sample. The observation might be explained partially by the 
unpaired normalization that Birdsuite, PennCNV, and GAP performed doing the 
preprocessing step. The performance of paired PSCBS in detecting CN gains and losses 
indicates the weakness and limitations of this algorithm in tackling aneuploid tumor 
samples. CNAG, PICNIC, ASCAT and TAPS show similar performances in detecting 
CN alterations in the pure tumor. However, the proportion of copy number gains detected 
by PICNIC drops drastically as the proportion of non-malignant DNA increases. This 
result stems from the ability of PICNIC to consider mixture of non-tumor DNA in the 
sample, because the three methods that can account for this show much less loss of ability 
to identify CNAs as the proportion of tumor in the sample decreases. CNAG and TAPS 
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both successfully detected around 25% LOH in the pure tumor, and then the proportion 
of LOH detected by these two samples increased in 70% tumor sample (Figure 22C). 
This may be due to misinterpretation of allelic imbalance as LOH in some regions. The 
power of CNAG to infer LOH regions is kept steady while the TAPS detects almost no 
LOH when the tumor content at or below 50%: TAPS’s performance degrades markedly 
in samples with <50% tumor content. ASCAT shows almost no loss in its ability to detect 
LOH in samples with very low proportions of tumor cells (Figure 22C); it thus may be 
the most suitable algorithm for detecting LOH in samples with low tumor content. Figure 
23 shows details of LOH analyses on chromosome 1 by various methods. As BAF 
gradually shrinks to 0.5 with the decrease of tumor content, fewer LOH regions were 
called. However, CNAG, PICNIC and ASCAT still preserve some ability to detect LOH 
even when there is only 30% tumor content.  
In addition, we tested the sensitivity and specificity of those methods by 
analyzing CNA and LOH using an approach first reported in [185] (Figure 24). This 
approach takes regions of CNA as real when they are called by five of the eight programs 
in the samples with 100% tumor content. Analogously, it takes regions of LOH as real if 
they are called by four out of the six programs that generate LOH estimates. The pattern 
of sensitivities of different methods is similar to the pattern of proportions of alterations 
found by these methods. With one exception, all the programs show high specificities in 
the analyses.  The exception is paired PSCBS in analyzing 70% tumor, which over-calls 





We compared eight commonly-used tools for analyzing CNA and LOH in tumors 
assayed by Affymetrix SNP 6.0 arrays. We evaluated their performances in a triploid 
tumor in a dilution series representing 100%, 70%, 50%, and 30% tumor cells mixed with 
non-malignant cells.  A spectral karyotype of the tumor was available to provide 
information on copy number independently of the Affymetrix data. 
We found that ASCAT performed the best with respect to sensitivity and 
specificity for detecting CNA and LOH. ASCAT is especially stable in calling LOH from 
samples with tumor content as low as 30% (Figure 24C). In addition, we found that 
CNAG,  although it does not estimate and adjust the tumor content, nevertheless 
performs well in estimating CNA and LOH in samples with lower tumor proportion. We 
conclude that ASCAT and CNAG are the best two choices among the eight tools to 
obtain accurate estimates of CNA and LOH from paired tumor-normal samples assayed 
by Affymetrix SNP 6.0 arrays. ASCAT is written in R and its parameters can be changed 
by programmers, but not by end users. Therefore, it is more suitable for labs with 
computational expertise. CNAG has a more user-friendly interface and is more 






FIGURE 7. Flowchart of SNP array data processing procedure for CNA and LOH 
detection.   





FIGURE 8. The clustering and pattern recognition algorithms used by GAP and 
TAPS. 
The graphs were generated from the SNP array data for the lung tumor cell line NCI-
H1395 (100% tumor content). (A) GAP uses a scatter plot of LRR by allelic difference, 
with the best-fitting model that allows interpretation of the CN and LOH states for all 
clusters. The numbers in the colored boxes (e.g. 2/1) indicate that the total copy number 
for segments in the cluster is 2 and that the B alleles have 1 copy. (B)  TAPs uses a 
scatter plot of LRR by allelic imbalance ratio. The graph shows allele-specific copy 
numbers determined for each cluster. For example, “3m1” indicates that a total copy 






FIGURE 9. Comparison of CNA and LOH detection across the genome for different 
methods at different proportions of tumor and non-malignant cells.  
Proportions of CN gains, losses and LOH are based on the ratio of altered SNP number to 
the total SNP number. Copy number gain refers to regions with > 2 copies and copy 






























































































FIGURE 10. LOH on chromosome 1 at varying proportions of tumor DNA as 
inferred by six programs.  
100%, 70%, 50%, and 30% indicate the proportion of tumor cells in the dilution series. 
Each graph contains four rows. The first row is the LRR normalized data along 
chromosome 1. The second row is the raw BAF data, and the third row is the BAF data 
after normalization by TumorBoost. The colored lines in the fourth rows represent the 




FIGURE 11. Comparison of sensitivities (A, B, C) and specificities (D)for different 
methods.  
For panels A, B, and C, the Y axes indicate the proportion of assumed real events 
detected (calculated by numbers of SNPs). For copy number alteration, sensitivity was 
calculated as the ratio of the number of altered SNPs detected by the given method to the 
number of SNPs detected by five out of eight of the programs. For panel D, the Y axis 
indicates the proportion of assumed real 2N regions without LOH that were determined 
as such by each method. Common unaltered regions were defined as the heterozygous 
copy number 2 called by at least five out of the eight methods and the specificity was 
calculated as the percentage of unaltered SNP number detected by the specific method to 










































































































































CHAPTER 3 GLOBAL ANALYSIS OF LOSS OF HETEROZYGOSITY AND 
GENOMIC COPY NUMBER ALTERATIONS IN GASTRIC CANCER 
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Gastric cancer is the second leading cause of cancer death worldwide but has been 
little studied compared with other cancers that impose similar burdens on public health. 
Gastric cancers often undergo loss of heterozygosity (LOH), sometimes resulting in the 
inactivation of tumor suppressor genes. Therefore, regions that are frequently and 
independently subject to LOH are likely to harbor tumor suppressors. However, patterns 
of LOH across gastric tumors have yet to be comprehensively studied by the most 
sensitive method currently available: high-density single-nucleotide polymorphism 
arrays. Here we report the results of genome-wide assessments of LOH and copy number 
alterations in 77 gastric adenocarcinomas. We used an array that assays genotype and 
allelic copy number at 906,600 single nucleotide polymorphisms. LOH is prevalent; on 
average 27% of each tumor genome was subject to LOH. The analysis of LOH implicates 
well-known tumor suppressors, including TP53 (61% of the tumors), CDKN2A (58%) 
and APC (42%). This analysis also implicates a candidate tumor suppressor, DOCK8, 
which, to our knowledge, has not been previously linked to gastric carcinogenesis. We 
also found that TP53 mutations occur almost exclusively in samples with LOH at that 
gene, confirming the important role of LOH in its inactivation. In addition, our analysis 
was able to detect somatic homozygous deletions in a mixture of tumor and non-
malignant DNA, which allowed us to survey these deletions as well. The systematic and 
broad characterization of LOH and homozygous deletions presented here can serve as 
resource to aid in the future identification of new driver genes in gastric 




Gastric cancer is the fourth most common cancer in the world and the second 
most common cause of cancer death [215]. In 2008, it caused 738,000 deaths (10% of all 
cancer-related deaths) [1]. Gastric cancer is especially prevalent in East Asia, Eastern 
Europe, and parts of Central and South America [1]. Current treatments have only slight 
survival benefits. Except in Japan, where endoscopic screening is common, the overall 
five year survival rate is only 20-25% [216].   
Although there have been many studies of LOH in gastric cancer, due to the 
limitations of previously available technologies, most have focused on small 
chromosomal regions or have assayed only a few markers on each chromosome arm. In 
particular, there were many studies based on restriction-fragment length polymorphism 
and microsatellite markers in specific genomic regions, which found that several tumor 
suppressor genes (TSGs), including TP53, APC, and DCC are often affected by LOH in 
gastric cancer [134, 155, 157, 162, 217-219]. In addition, surveys that sampled a few loci 
on each chromosome arms have identified LOH affecting every chromosome arm [135, 
154], Nevertheless, genome-wide patterns of LOH across multiple gastric tumors have 
yet to be systematically studied by the most thorough and sensitive method currently 
available: high-density single-nucleotide-polymorphism (SNP) arrays.  
In addition to LOH, gastric cancers also commonly possess genomic copy-
number alterations (CNAs), i.e. genomic amplifications and deletions. The most recent 
studies used comparative genomic hybridization (CGH), array CGH, or SNP arrays and 
have provided an extensive and detailed view of CNA in gastric cancer [23, 80, 81, 217, 
220]. Some CNAs have clinical implications. Amplification and over-expression of MET 
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and ERBB2 are associated with poor survival [84, 86, 87], as is KRAS amplification [23]. 
In addition, there is evidence that patients with amplifications of FGFR2 benefit from 
dovitinib treatment [23]. 
Here we delineate a high-resolution, comprehensive view of genomic regions 
subject to LOH and CNA, including homozygous deletion, based on microarray assays of 




3.3 Materials and Methods 
3.3.1 Patients and Samples 
Primary gastric adenocarcinomas and matched non-malignant tissue samples were 
obtained from Singapore Health Services with approval from the institutional review 
board. All samples were obtained with signed informed consent. Table 3 summarizes 
histopathological and patient characteristics. 
3.3.2 DNA Extraction and Hybridization 
Genomic DNAs from snap-frozen gastric tumors and matched non-malignant 
gastric tissues was extracted using a Qiagen genomic DNA extraction kit. The DNA was 
then hybridized to Affymetrix Human Mapping SNP 6.0 arrays (Affymetrix, Santa Clara, 
CA) according to the manufacturer’s protocol. The chips were scanned with a GeneChip 
scanner using the Affymetrix GeneChip Operating Software. SNP positions were 
represented according to the hg18 (build 36) version of the human genome sequence. 
Some of the array data were previously published in [23]. However, these data were not 
previously analyzed for LOH, allelic imbalance, or homozygous deletions.  
3.3.3 SNP Array Data Pre-processing 
We used CRMA-v2 (Copy-number estimation using Robust Multichip Analysis 
version 2) [173] to extract intensity values for both alleles of each SNP from the SNP 
array data in the .CEL files. In this process, CRMA attempts to account for (1) crosstalk 
between alleles, (2) probe sequence effects, and (3) the effects of the varying sizes of 
fragments generated by restriction enzyme digestion prior to hybridization. We then 
processed each tumor-and-non-malignant pair with TumorBoost [214] to increase the 
signal-to-noise ratio of the allele-specific signals. This made it substantially easier to 
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detect allelic imbalance. Matched non-malignant samples were used as the reference for 
generating log2 relative ratios (LRRs) and B-allele frequencies (BAFs) for the SNPs. The 
LRR of a SNP is the log2 of the signal intensity at that SNP (summed over both alleles) in 
the tumor sample divided by the signal intensity in the matched non-malignant sample. 
The BAF of a SNP is the proportion of the total signal in the tumor deriving from the 
non-reference allele. (The non-reference allele is designated the B allele, whence the term 
B-allele frequency.)  
3.3.4 ASCAT Profiling of Allele-Specific Copy Numbers 
We used ASCAT (Allele-Specific Copy number Analysis of Tumors) [186] 
versions 2.0 and 2.1 to estimate allele-specific copy numbers from the LRRs and BAFs 
while accounting for the effects of cancer-cell polyploidy and aneuploidy and the 
admixture of DNA from non-malignant cells (FIGURE 12). We selected ASCAT after 
evaluating several other analytical software packages, including CNAG (Copy Number 
Analyzer for GeneChip) [179] and GAP (Genome Alteration Print) [183]. For evaluation 
we used published data from a dilution series of cancer cell-line DNA mixed with DNA 
from non-malignant tissue from the same person [185]. We evaluated the software 
packages based on their (1) ability to detect LOH, allelic imbalance, and CNA in samples 
with a low proportion of tumor cells and (2) ability to be used in semi-automated fashion 
from the command line. Details of the evaluation are presented in Chapter 2. We made 
several modifications to ASCAT to work effectively with Affymetrix Human Mapping 
SNP 6.0 arrays, as detailed in Table 10. 
The main inputs to ASCAT are LRRs and BAFs computed from DNA samples 
from a tumor and matched non-malignant tissue as described above (Figure 12A,B). 
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ASCAT analyses these for SNPs that are heterozygous in the non-malignant sample, and 
therefore informative with respect to LOH and allelic imbalance. ASCAT smoothes 
random SNP-to-SNP variation in LRRs and BAFs by segmentation. The green dots in 
Figure 12A and B show the segmented LRR and BAF values, superimposed on the 
original, unsegmented values, which are indicated by the red dots. After segmentation, 
ASCAT generates genome-wide allele-specific copy number profiles (Figure 12D). The 
profiles estimate (1) the proportion of tumor and non-tumor cells in the tumor sample 
(“aberrant cell fraction” in Figure 12D), (2) allele-specific copy numbers of chromosomal 
segments across the genome, and (3) reliability scores for these estimates (Figure 12E). 
ASCAT also provides an average ploidy for each tumor sample, which is the average of 
the copy numbers of informative SNPs across the genome (“Ploidy” in Figure 12D). 
3.3.5 Cell Culture 
Six gastric cancer cell lines (YCC10, SCH, NUGC3, IM95, N87 and YCC16) and 
one gastric mucous epithelium cell line (HFE145) were selected for studies of candidate 
TSGs PTPRD and DOCK8. Cell lines IM95 and HFE145 were cultured in Dulbecco's 
modified Eagle medium (DMEM) with 10% FBS (fetal bovine serum) and 10mg/L 
insulin. Cell lines YCC16 and YCC10 were cultured in Minimum Essential Medium 
Eagle medium (MEM) with 10% FBS. Cell lines SCH, NUGC3 and N87 were cultured in 
Roswell Park Memorial Institute medium (RPMI) with 10% FBS. 
3.3.6 Preparation and Transfection of siRNA 
The siRNAs targeting PTPRD and DOCK8 were purchased from Dharmacon 
(www.dharmacon.com). Cells were seeded onto 60mm culture plates at a density of 2×
10
5
 cells/mL and cultured overnight to reach 80% confluency before transfection. Cells 
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were transfected with 5nM of siRNA using DharmaFECT reagent in opti-MEM serum-
free medium at 37°C in 5% CO2 atmosphere for 24h. Then the medium was removed and 
replaced with the original culture medium.  
3.3.7 Western Blot Analysis 
Cells were cultured until 80-90% confluency and proteins were extracted with 
lysis buffer (2% SDS). Proteins were separated on 6% SDS-PAGE, and then transferred 
to nitrocellulose membranes. After blotting with 5% non-fat dry milk and 0.1% Tween 20 
in Tris-buffered saline, membranes were incubated separately with either rabbit 
polyclonal anti-PTPRD or rabbit polyclonal anti-DOCK8 antibodies (1:200 diluted in 1% 
non-fat dry milk). The membranes were subsequently incubated with goat anti-rabbit 
secondary antibodies and screened by Odyssey® Imager of Li-COR.  
3.3.8 Cell proliferation assays 
Cell proliferation assays were performed with a CellTiter96 Aqueous 
Nonradioactive Cell Proliferation Assay kit (Promega) following the manufacturer’s 





We analyzed 113 gastric tumors with their paired adjacent non-malignant tissues 
using ASCAT. For 77 of the 113 pairs, ASCAT was able to estimate allele-specific copy 
numbers across the genome. ASCAT was unable to estimate allele-specific copy numbers 
for the remaining pairs for the following reasons (Table 11): (1) excessively variable 
LRR data that ASCAT was unable to segment reasonably (12 tumors, Figure 13A); (2) 
BAF values that are almost uniformly 0.5, which could be due to a tumor genome 
completely lacking LOH or allelic imbalance or, alternatively, to a very low proportion of 
tumor cells contributing to the DNA sample (22 tumors, Figure 13B); or (3) apparently 
low tumor content as evidenced by very little variation in the segmented LRRs and few 
divergences of the BAFs from 0.5 (2 tumors). The samples that ASCAT was not able to 
analyze had lower pathologist-estimated tumor proportions compared to samples that 
ASCAT succeeded in analyzing (p = 0.034, one-sided Wilcoxon rank-sum test, Table 3, 
Figure 14A). Furthermore, the minimum tumor cell proportion that ASCAT was able to 
estimate was 18%, suggesting that it is not able to analyze samples with content lower 
than this (Figure 14B). These two observations implicate low tumor content as a possible 
major reason that ASCAT could not estimate allele-specific copy number for some 
samples. 
LOH Landscape in Gastric Cancer. 
LOH is prevalent in gastric cancer (Figure 15, Table S3): on average, 26.8% of 
each gastric cancer genome was subject to LOH (range 0.13% to 77.7%). LOH is also 
pervasive: 98% of the SNPs assayed were subject to LOH in at least 10% of tumors. We 
focused on the 10 regions that were subject to LOH in ≥ 35% of the tumors (Table 4). 
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Chromosome arm 17p, which contains TP53, is the region most frequently subject to 
LOH, and 61% of the tumors show LOH there. Chromosome arms 9p (58% of tumors, a 
region containing the well-known TSG CDKN2A) and 5q (42% of tumors, a region 
containing the well-known TSG APC) also frequently undergo LOH. Several other TSGs 
in regions subject to frequent LOH include MAP2K4, NCOR1, and CDKN2A (Table 4). 
Copy-number neutral LOH (CNNLOH) accounted for an average of 51% of LOH in each 
sample. However, in some LOH peaks, for example the one in 18q, more than half of the 
tumors with LOH have hemizygous deletions; 18q contains the likely TSG DCC (deleted 
in colorectal cancer). 
Recurrent Somatic CNAs in Gastric Cancer 
Because ASACT estimates allele-specific copy number in order to identify 
regions of LOH, it also detects CNAs. For this analysis, we considered a region to be 
subject to CNA in a sample if the ASCAT-determined integral copy number was less 
than or greater than two. We observed a total of 2,037somatic CNAs, (954 gains and 
1,083 losses) across the 77 tumors; the mean number of copy number gains per sample 
was 12 (median=7) and the mean number of losses was 14 (median=6). With the ASCAT 
profile for each sample as input, GISTIC (Genomic Identification of Significant Targets 
in Cancer [221]) identified 40 regions (17 gains and 23 losses) that underwent significant 
CNA (Figure 16, Tables 5 and 6). The regions of significant CN gain and loss identified 
in this study are similar to those identified in a previous study using different 
methodologies in 193 tumor samples from the same collection [23]. 
Because the current analysis considers the effects of tumor aneuploidy and 
mixture of non-malignant genomes in the tumor samples (Figure 16), it can identify 
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homozygous deletions. The highest frequency of homozygous deletion involves a region 
on 3p that contains no well-characterized genes (6 tumors). Other recurrent homozygous 
deletions are in within chromosome arms 8p (4/77) and 18q (4/77) (Figure 15D, Table 7). 
The well-known TSGs CDKN2A (p16, ARF), AXIN1, and SMAD4 were each 
homozygously deleted in 2 tumors. 
Relation between Genomic Alterations and Tumor Characteristics  
In order to investigate the biological implications of LOH and CNA in gastric 
cancer, we compared LOH and CNA proportions among different clinical subgroups. We 
found that tumors from males tend to have higher proportions of LOH than those from 
females (Figure 17A, p=0.04, Wilcoxon rank sum test, not significant considering that we 
tested four hypotheses). There were no significant relationships between gender and any 
of CNNLOH proportion, CN loss proportion, or CN gain proportion. (Figure 17B-D). 
We also evaluated the LOH proportions in intestinal compared to diffuse gastric 
tumors. We found no significant relationship between CNNLOH or CNA proportion and 
these two histological subtypes (Figure 18).  
LOH and TP53 mutations  
We also found evidence that TP53 mutations are associated with higher levels 
genomic instability as detected by ASCAT. We previously reported results of screening 
for mutations in the TP53 hot spots (exons 4, 5, 6, 7, 8 and 9) [78] in 56 of the 77 tumors 
that we analyzed. Among these 56 tumors, those with TP53 mutations had a higher 
proportion of the genome affected by CNAs (p = 0.029 by Wilcoxon rank-sum test, 
Figure 19). This result is consistent with previous studies that have linked genomic 
instability to mutations on TP53 [222, 223].  
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In addition, we found that TP53 mutations occurred almost exclusively in tumors 
with LOH at that gene: only three samples had TP53 mutations but no LOH at that gene 
(p=4.75e-4, Fisher's exact test, Table 8). This is consistent with Knudson’s model that 






Genome-wide analyses of CNA and LOH are challenging due to the mixture of 
malignant and non-malignant genomes in tumor samples. No standard method has 
emerged as the most appropriate to accurately estimate allele-specific copy numbers in 
tumors with low proportions of malignant cells. ASCAT performed well in our 
evaluation of it in a dilution series in the face of a low proportion of malignant cells [224]. 
Nevertheless, it appears that ASCAT's ability to complete its analysis rapidly approaches 
nil when the proportion of malignant cells is < 20% (Figure 14B). Indeed, it is impossible 
for any analytic approach to distinguish a tumor sample consisting almost entirely of non-
malignant cells from a sample consisting entirely of malignant cells with normal genomes 
that completely lack large-scale genomic aberrations. ASCAT was not able to generate 
allele-specific-copy-number profiles for 22 tumor samples with flat BAFs (Figure 13B). 
If these included some tumors that completely lacked genomic aberrations, then we 
would have overestimated the proportion of gastric adenocarcinomas with LOH, allelic 
imbalance, and CNA. We note, however, that on the whole, earlier genome-wide surveys 
found similar or higher estimates of the proportions of tumors affected by LOH [135, 154] 
or CNA [81].  
In addition, ASCAT was unable to complete its analysis of 12 tumors for which 
the LRRs were excessively variable (Figure 13A). In most tumors  for which ASCAT 
was able to generate an allele-specific-copy-number profile, the standard deviations of 
the segmented LRRs and BAFs are tightly correlated (blue circles in Figure 20). For the 
samples with excessively variable BAFs, however, the standard deviations of the BAFs 
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are relatively lower (red squares in Figure 20). Indeed, the LRRs change frequently 
without corresponding changes in BAFs in these tumors.  This then suggests the high 
variability of the LRRs represent an experimental artifact rather than a characteristic of 
these gastric cancer genomes. 
Comparison to previous findings on CNA in gastric cancer 
Compared to the CN amplification pattern in 34 gastric cancer cell lines found by 
Tada et al [217], we found similar regions that are frequently amplified in gastric cancer, 
including 8q, 11p, and 20q. We also corroborated several other regions that were 
previously reported to frequently undergo CNA [81-83]. When comparing the CNA 
landscape in our analysis to a previous CN study using 193 tumor samples from the same 
collection [23], we found marked similarity in the CNA patterns, which confirmed 
several previous findings, such as the amplifications of FGFR2 and ERBB2.  
Comparison to previous findings on LOH in gastric cancer 
Several studies have found that LOH occurs more often in intestinal-type gastric 
tumors than diffuse-type tumors [225, 226]. However, this was not observed in other 
studies [132, 154, 156]. The present whole-genome analysis found no evidence of 
differences in the proportion of LOH between the two types (Figure 19A,B). 
Previous univariate analyses indicated that patients with low levels of LOH had 
better survival than those with high levels of LOH or non-detectable LOH [101, 217]. To 
assess the prognostic impact of LOH in gastric cancer in our data, we conducted a Kaplan 
Meier survival analysis comparing patients with high versus low proportion of LOH. We 
found no evidence of differences between the two groups (Figure 21A). Multivariate 
analysis in a Cox proportional hazards model that treated the proportion of LOH as a 
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continuous variable likewise showed no evidence that survival was related to the 
proportion of LOH (Table 9). We also found no evidence of an effect of average ploidy 
on survival (Figure 21B).  
Candidate tumor-suppressor genes subject to frequent LOH 
We found that the short arm of chromosome 9 (9p) is subject to frequent LOH in 
gastric cancer (58%). Several studies have reported similar observations, with frequencies 
ranging from 22% to 64%. The well-known TSG CDKN2A (p16) is located on 9p21, and 
is mutated in numerous tumor types [227-229]. This gene is frequently deleted or 
hypermethylated [230-235] in gastric cancer, and in our analysis this gene was 
homozygously deleted in 2 tumors (Figure 15D). However, it is possible that there are 
other TSGs in this region that contribute to gastric carcinogenesis. Two genes that look 
promising in this regard are PTPRD (protein tyrosine phosphatase, receptor type, D) and 
DOCK8 (dedicator of cytokinesis 8). 
PTPRD is inactivated by gene deletion or mutation in various cancers, including 
lung cancer, neuroblastoma, glioblastoma, melanoma, and squamous cell carcinoma 
[236-241] and was previously noted to undergo LOH in gastric cancer [217]. In addition, 
PTPRD was homozygously deleted in 2 out of 77 gastric tumors. PTPRD also interacts 
with MIM, a potential metastasis suppressor gene, in regulating cytoskeletal remodeling 
[242]. PTPRD’s ability to dephosphorylate STAT3 is abrogated by cancer-specific 
mutations in PTPRD [239]. The evidence above supports the hypothesis that PTPRD acts 
as a TSG.  
DOCK8, another candidate TSG in 9p is a guanine nucleotide exchange factor 
(GEF) that is responsible for activation of Rho GTPases by exchanging bound GDP for 
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free GTP. Homozygous deletion and reduced expression of DOCK8 were observed in 
lung cancer [243-245]. We also observed increased mRNA expression levels of DOCK8 
in tumors compared to non-malignant gastric epithelium (p=0.02, data are not shown). 






This genome-wide survey of LOH, allelic imbalance, and CNA, including 
homozygous deletions, in 77 gastric adenocarcinomas provides a more systematic and 
detailed picture than previously available. Because the regions commonly affected LOH 
and CNA are broad and encompass many genes, information about these regions alone is 
not sufficient to unambiguously identify driver genes. In the future, when integrated with 
information on somatic point mutations and experimental studies, the results from this 
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FIGURE 12. Example ASCAT profile and allele-specific copy numbers.  
(Data for tumor 97005.) (A) LRR. The x-axis shows the indices of autosomal SNPs 
that are heterozygous in the non-malignant sample. The y-axis shows the LRR value of 
SNPs in the tumor relative to the non-malignant sample. Green dots show ASCAT’s 
segmentations. (B) BAFs for the SNPs plotted in A. Green lines show ASCAT’s 
segmentation. (C) The solution space for the two parameters "ploidy" and "aberrant cell 
fraction", with the location of the chosen values marked with an “X”. (D) ASCAT’s 
model of allele-specific copy numbers. The y-axis indicates the estimated (integer) 
chromosomal copy number. Red and green lines indicate the more common and less 
common chromosomal haplotypes, respectively. The lines are vertically offset slightly to 
avoid superimposition. (E) The aberration reliability score, a measure of how well the 















FIGURE 13. Examples of tumor and non-malignant pairs that ASCAT was unable 
to analyze.  





FIGURE 14. Relationship between tumor content and ASCAT’s ability to generate 
an allele-specific-copy-number model.  
(A) Pathologist-estimated tumor proportions in samples for which ASCAT was able or 
unable to generate allele-specific-copy-number models. P value by one-sided Wilcoxon 






FIGURE 15. Frequencies of LOH and CNA across 45 gastric tumors.  
Several known TSGs are indicated. 





























FIGURE 16. Identification of significant somatic copy number alterations across 
gastric cancer by GISTIC.  
The y-axes are the positions across the autosomal genome, and the x-axes are the GISTIC 
q-values. Several known or putative gene cancer-related genes are indicated in peaks that 













FIGURE 18. Comparisons of proportions of LOH and CNA in gastric tumors 




FIGURE 19. Relationship between TP53 mutation and proportion of genome 
subject to CNA.  







































FIGURE 21. Kaplan-Meier survival analysis comparing outcomes by proportion of 
LOH and average ploidy.  
(A) Patients with high proportions of LOH (24 patients, >30% of the genome) versus 
patients with low proportions of LOH (21 patients, <30%). (B) Patients with high tumor 
ploidy (21 patients, average ploidy >2.6) versus patients with low tumor ploidy (24 
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Median 35% 60% 20% 
  
Gender Female 41 23 18 0.058 Fisher's exact 
 









Intestinal 62 46 16 
  
 
Mixed 7 5 2 
  
TNM Stage I 14 10 4 0.956 Chisq 
 
II 20 13 7 
  
 
III 61 41 20 
  
 









G-DIF 45 26 19 
  
 




























40 29 11 
  
 
Well diff 4 3 1 
  
T: t-test; G-INT: genomic intestinal [110]G-DIF: genomic diffuse [110]; NC: not 
classifiable; Chisq: chi-squared test; diff: differentiated. 
a 
Medians and log-rank test calculated by the survfit and survdiff functions in the R 
package “survival” (http://cran.r-project.org/web/packages/survival/index.html) [246]. 
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TABLE 4. Regions with LOH in ≥35% of gastric adenocarcinomas. 







Cancer genes in region 
17p 6,689 19,117,656 19.1 47 0.61 




11,219,652 30,245,385 19.0 45 0.58 CDKN2A (p16, ARF) 












5,374,196 36,322,279 9.7 33 0.43 EVC2 
4q13.1-
q24 
58,284,649 187,905,789 75.2 33 0.43 CDS1, NFKB1 
18q12.1-
q22.3 
28,823,732 69,726,488 40.9 33 0.43 
DCC, ELP2, SMAD2, 
SMAD4 
3p14.2 60,114,683 60,463,734 0.3 33 0.43 FHIT 
5q13.2-
q31.3 
70,702,961 141,259,534 70.6 32 0.42 PIK3R1, APC, CTNNA1 
9q31.1-
q31.3 




1,543 8,733,340 8.7 20 0.26 ROCK1 
21q21.1-
q21.2 














TABLE 5. Summary of frequently deleted regions. 
Location Start End 
Size 
(Mb) 
q-value Genes in the region 





















181,383,219 182,941,584 1.6 
6.40E-
07  




21q21.1 19,272,221 19,819,004 0.5 
5.70E-
06  





58,333,900 59,098,226 0.8 
5.00E-
05  














14q11.2 21,418,624 22,057,861 0.6 
1.03E-
03  
22q13.31 43,195,272 46,946,850 3.8 
2.06E-
03  
6p25.3 1,846,495 2,122,022 0.3 
2.62E-
03  




















15q15.1 38,166,323 43,737,772 5.6 
1.59E-
01 BUB1B,CASC5,HMGN2P46 
7q36.3 154,841,836 158,821,424 4.0 
1.94E-
01 MNX1 





TABLE 6. Summary of frequently amplified regions. 
Location Start End Size (Mb) q-value Genes in the region 
1q42.3 232,761,812 233,339,801 0.6 7.50E-02 
 
6p21.1 43,690,070 44,128,387 0.4 7.50E-02 
 
7p11.2 54,569,040 55,378,541 0.8 7.50E-02 EGFR 
7q21.2 91,763,193 92,799,547 1.0 7.50E-02 CDK6 
8q24.21 128,415,541 128,832,045 0.4 7.50E-02 MYC 
12p12.1 24,958,055 25,551,845 0.6 7.50E-02 KRAS 
13q22.1 72,589,238 73,243,304 0.7 7.50E-02 
 
15q26.3 94,252,474 100,338,915 6.1 7.50E-02 IGF1R 
17q12 34,863,650 35,320,545 0.5 7.50E-02 ERBB2, CDK12 
18q11.2 18,375,383 18,600,004 0.2 7.50E-02 
 
19q12 34,820,561 35,362,277 0.5 7.50E-02 CCNE1 
20q13.33 59,924,052 62,435,964 2.5 7.50E-02 SS18L1, CDH4 
11p13 34,438,885 35,369,622 0.9 8.41E-02 
 10q26.13 123,195,729 123,531,151 0.3 1.12E-01 FGFR2 
5p13.1 25,319,140 41,417,176 16.1 1.56E-01 IL7R,LIFR 
2q36.3 227,164,747 228,310,820 1.1 2.03E-01 




TABLE 7. Summary of regions with homozygous deletions in more than one sample. 
Chr Start End Size (Mb) 
# 
samples 
Genes in the region 
1 554,484 3,784,133 3.23 3 TP73, PRDM16 
2 239,627,708 242,697,433 3.07 2 HDAC4 
3 60,278,544 60,572,503 0.29 5 
 
4 26,568 4,023,209 4.00 2 WHSC1,FGFR3,GAK 
5 81,949 2,012,324 1.93 2 TERT 
6 1,851,860 2,109,454 0.26 2 
 
8 103,565 2,188,481 2.08 4 CSMD1 
8 2,188,792 4,197,712 2.01 3 CSMD1 
8 4,198,154 11,468,631 7.27 2 CSMD1 
8 11,532,066 43,898,071 32.37 2 PCM1,WHSC1L1,FGFR1,WRN,HOOK3,MAP2K1 
9 21,007,240 22,088,619 1.08 2 CDKN2A,CDKN2B 
11 188,510 3,443,300 3.25 2 CDKN1C,HRAS,CARS 
12 6,415,872 6,555,449 0.14 2 
 14 21,443,181 22,053,063 0.61 2 
 14 83,885,524 85,056,916 1.17 2 
 14 98,674,664 106,356,482 7.68 2 AKT1,CDC42BPB,BCL11B,HSP90AA1 
16 26,671 2,203,517 2.18 2 TSC2 
16 77,251,379 77,276,096 0.02 2 WWOX 
16 84,294,768 84,458,328 0.16 3 
 16 86,129,781 88,690,776 2.56 3 FANCA,CBFA2T3 
18 46,825,370 69,678,634 22.85 2 BCL2,MALT1,DCC,KDSR,SMAD4 
18 69,679,190 75,288,153 5.61 3 
 18 75,300,011 76,116,029 0.82 4 
 20 59,334,918 62,382,907 3.05 2 SS18L1 
21 9,928,594 19,664,061 9.74 3 
 21 19,668,806 22,054,808 2.39 2 

























TABLE 9. Cox proportional hazards analysis provides no evidence that LOH 
proportion influences prognosis. 
Variable coef exp(coef) se(coef) z p 
LOH proportion 0.1948 1.215 1.09 0.179 0.86 
Age 0.0096 1.01 0.016 0.598 0.55 
Gender -0.4245 0.654 0.448 -0.949 0.34 
TNM Stage 1.0303 2.802 0.276 3.731 0.00019 
Adjuvanttreatment 0.2045 1.227 0.453 0.451 0.65 
Intestinal type 0.6084 1.837 0.452 1.347 0.18 
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970005 2.0 1.5 0.35, 0.65 85 100 
980011 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
980021 2.0 1.5 0.35, 0.65 85 100 
980029 2.0 1.5 0.35, 0.65 85 100 
980097 2.0 1.5 0.35, 0.65 85 100 
980156 2.0 1.5 0.35, 0.65 85 100 
980369 2.0 1.5 0.35, 0.65 65 100 
980390 2.0 1.5 0.35, 0.65 65 800 
980401 2.0 1.5 0.35, 0.65 85 100 
980417 2.0 1.5 0.35, 0.65 85 100 
980418 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
980437 2.0 1.5 0.35, 0.65 85 100 
980447 2.0 1.5 0.35, 0.65 65 100 
990005 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990010 2.0 1.9 0.35, 0.65 85 100 
990041 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990044 2.0 1.5 0.35, 0.65 85 100 
990046 2.0 1.5 0.35, 0.65 65 100 
990060 2.0 1.5 0.35, 0.65 85 100 
990069 2.0 1.5 0.35, 0.65 85 100 
990071 2.0 1.5 0.35, 0.65 85 100 
990090 2.0 1.5 0.35, 0.65 85 100 
990097 2.0 1.5 0.35, 0.65 85 100 
990098 2.0 1.5 0.35, 0.65 65 800 
990108 2.0 1.5 0.35, 0.65 65 100 
990111 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990119 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990170 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990172 2.0 1.9 0.35, 0.65 85 100 
990195 2.0 1.5 0.35, 0.65 85 100 
990203 2.0 1.5 0.35, 0.65 85 100 
990228 2.0 1.5 0.35, 0.65 85 100 
990247 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990275 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990300 2.0 1.5 0.35, 0.65 85 100 
990339 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990355 2.0 1.5 0.35, 0.65 85 100 
990396 2.0 1.5 0.35, 0.65 85 100 
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990412 2.0 1.5 0.35, 0.65 65 100 
990474 2.0 1.5 0.35, 0.65 85 100 
990475 2.0 1.9 0.35, 0.65 85 100 
990489 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
990515 2.0 1.5 0.35, 0.65 85 100 
2000040 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
2000068 2.0 1.5 0.35, 0.65 85 100 
2000085 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
2000088 2.0 1.5 0.35, 0.65 85 100 
2000169 2.0 1.5 0.35, 0.65 65 100 
2000175 2.0 1.5 0.35, 0.65 85 100 
2000201 2.0 1.5 0.35, 0.65 85 100 
2000242 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
2000286 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
2000303 2.0 1.5 0.3, 0.7 85 100 
2000362 2.0 1.5 0.35, 0.65 85 100 
2000403 2.0 1.5 0.35, 0.65 65 100 
2000433 2.0 1.5 0.35, 0.65 85 100 
2000441 2.0 1.5 0.35, 0.65 85 100 
2000877 2.0 1.5 0.35, 0.65 85 100 
2000892 2.0 1.5 0.35, 0.65 85 100 
20020011 2.0 1.9 0.35, 0.65 85 100 
20020448 2.0 1.5 0.35, 0.65 65 800 
20020720 2.0 1.5 0.35, 0.65 85 100 
20263644 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
32226415 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
38877042 2.0 1.5 0.35, 0.65 85 100 
46404174 2.1 1.5 0.35, 0.65 85 as determined by ASCAT 2.1  
47492137 2.0 1.9 0.35, 0.65 85 100 
57689477 2.0 1.5 0.35, 0.65 85 100 
57701999 2.0 1.5 0.35, 0.65 85 100 
58947266 2.0 1.5 0.35, 0.65 85 100 
61669256 2.0 1.5 0.35, 0.65 85 100 
66811693 2.0 1.5 0.35, 0.65 85 100 
73291145 2.0 1.5 0.35, 0.65 85 100 
76629543 2.0 1.5 0.35, 0.65 80 100 
87622942 2.0 1.5 0.35, 0.65 85 100 
91228050 2.0 1.9 0.35, 0.65 85 100 





TABLE 11. Tumors for which ASCAT was unable to estimate allele-specific copy 
numbers.  
Sample ID ASCAT fail reason Laurén classification Gender 
970003 Excessively variable LRR Diffuse Female 
970017 Flat BAF Diffuse Female 
980035 Flat BAF Intestinal Male 
980251 Flat BAF Diffuse Female 
980319 Flat BAF Mixed Male 
980327 Flat BAF Mixed Female 
980344 Excessively variable LRR Diffuse Female 
980386 Flat BAF Diffuse Female 
980436 Flat BAF Intestinal Female 
980442 Flat BAF Diffuse Female 
990015 Flat BAF Intestinal Male 
990024 Flat BAF Intestinal Male 
990068 Excessively variable LRR Diffuse Male 
990070 Apparently low tumor content Diffuse Male 
990089 Apparently low tumor content Intestinal Male 
990129 Excessively variable LRR Intestinal Female 
990136 Excessively variable LRR Intestinal Male 
990205 Excessively variable LRR Intestinal Female 
990413 Flat BAF Diffuse Male 
990424 Flat BAF Diffuse Male 
2000114 Flat BAF Intestinal Male 
2000159 Flat BAF Intestinal Female 
2000178 Flat BAF Intestinal Female 
2000238 Flat BAF Diffuse Female 
2000291 Flat BAF Diffuse Male 
2000346 Flat BAF Diffuse Female 
2000479 Flat BAF Intestinal Male 
2000617 Excessively variable LRR Intestinal Male 
2000920 Excessively variable LRR Intestinal Male 
2001159 Flat BAF Intestinal Male 
2001226 Excessively variable LRR Diffuse Male 
2001229 Flat BAF Diffuse Female 
2001241 Excessively variable LRR Diffuse Female 
37262942 Excessively variable LRR Diffuse Female 
43658255 Excessively variable LRR Intestinal Male 




3.10 Supplementary Figure:  
(Experimental analysis did not show significant evidence that PTPRD and DOCK8 have 
functional relationship to tumorigenesis) 
 
Figure 22. Western blot of proteins PTPRD and DOCK8 using various cell lines. 













FIGURE 23. DOCK8 and PTPRD siRNA knock-down analysis show no significant 

















CHAPTER 4 LOH ANALYSIS IN CANCER RESEARCH 
4.1 Results 
4.1.1 LOH Analysis of Candidate TSG detected by Whole-Exome Sequencing in 
Gastric Cancer  
Exome sequencing by next-generation sequencing approaches is a newly 
developed technique. It is cheaper compared to whole-genome sequencing as it targets 
only the coding sequences. The exome is the part of the genome that is composed by 
exons, the coding regions of genes that can be translated into protein and the untranslated 
regions flanking them (UTRs). Although exons only occupy approximately 1% of the 
genome, mutations on exons comprise around 85% disease-related mutations [247]. 
Therefore, exome sequencing is an efficient way to discover novel oncogenes and tumor 
suppressor genes (TSGs) with functional changes due to mutations in various diseases.  
Loss of heterozygosity (LOH) is usually a second hit in the Knudson’s two-hit 
model to lose the second normal allele after one allele of the TSG has already been lost 
because of mutation [4]. Thus, LOH analysis facilitates the discovery of TSGs and 
supports the findings of mutational analysis by exome sequencing. 
We have introduced the epidemiology and etiology in Chapter 1. In our recent 
study, we sequenced the coding regions of ~18,000 genes in 15 gastric cancers with their 
matched normal samples and found 718 nonsynonymous mutations in 661 genes [78]. In 
addition to well-known tumor related genes such as TP53, PIK3CA and CTNNB1, we 
also revealed 26 genes that are recurrently mutated in gastric cancer (mutations found in 
more than 2 tumors out of the 15 discovery dataset). Among these genes, FAT4 is 
especially interesting. It belongs to the E-cadherin family and may be involved in the 
99 
 
Wnt/planar cell polarity signaling pathway. Two non-silent mutations were found in the 
15 gastric adenocarcinomas by exome sequencing and a further Sanger sequencing in the 
additional 95 gastric cancers discovered four more mutations. We applied the LOH 
analysis (as described in Chapter 2 Methods) using ASCAT [186] on these six tumors 
with FAT4 mutations and found that 4 out of 6 samples also have LOH at FAT4 (Figure 
25),  which supports the Knudson’s model regarding the loss of function of TSGs. The 
combination of the exome sequencing mutational analysis and the SNP array LOH 
analysis reveals that FAT4 is a candidate TSG in gastric cancer. Therefore, the FAT4 
silencing experiments were conducted on cell lines with wild-type FAT4 and FAT4 
silencing result in a significant increase in cell proliferation. This suggests that FAT4 
functions as a tumor suppressor to suppress the tumor proliferation. 
4.1.2 CNA and LOH Analysis in Both SNP Array and Next-Generation 
Sequence Data 
Although next-generation sequencing is now widely used to detect somatic 
mutations in cancers, the data can also be used for CNA and LOH analysis. The data can 
be used to detect: (1) gains or losses of chromosomal segments, and (2) LOH, or more 
generally, allelic imbalance, which is the presence of unequal numbers of maternal and 
paternal chromosome segments. We used a modified version of ASCAT algorithm [186], 
which is called RDAAC (Read Depth And Allele Count), to identify CNA and LOH from 
next-generation sequencing data and compared the results with those from the Affymetrix 
SNP 6.0 arrays. The general mechanisms of ASCAT and RDAAC are the same, except 
that RDAAC calculated LRR and BAF based on read depths of alleles and did not need 
to adjust for BAF contraction effect. To get a measure analogous to LRR obtained from 
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SNP arrays, RDAAC uses the log2 ratio of read depths in the tumor sample to read depth 
in the matched non-malignant sample. To get a measure of the BAF, RDAAC uses the 
ratio of reads with the variant allele (i.e., the B allele), to total number of reads. 
Results of analyses based on SNP array data and on whole-exome sequencing 
data are similar (Figure 26). In general, RDAAC analysis on next-generation sequencing 
and ASCAT analysis on SNP array data found that the tumor is hypertetraploid (average 
ploidy of 4.38 by RDAAC and 4.37 by ASCAT) and that the sample has ~70% tumor 
content (67% by RDAAC and 71% by ASCAT). We can observe a clearer separation of 
BAF values in the next-generation sequencing data than in the SNP array data (for 
example, on chromosomes 3 and 4). This may be a consequence of a nearly direct 
assessment of BAF in next-generation sequencing data compared to possibly non-linear 
measurements of allele-specific intensities in the Affymetrix SNP chip technology. 
Therefore, RDAAC analysis on next-generation sequencing is more efficient at detecting 
LOH and allelic imbalance in samples with lower tumor content. However, we also 
notice a higher coverage of SNPs in the Affymetrix data, which facilitates the detection 
of small alterations in CN and allelic balance. The larger number of SNPs in the 
Affymetrix data compared to the exome-data is a simple consequence of the fact that the 




FIGURE 24. The ASCAT profile of two gastric tumors assayed by Affymetrix SNP 6.0.  
LOH was found at FAT4 in tumors that also have missense somatic mutations in  
FAT4. Panels A, B, and C refer to tumor 990515 and panels D, E, and F refer to 2000068. FAT4 
is located in the middle of the long arm of chromosome 4.  
(A, D) LogR ratio (LRR). Each red dot shows, for a single SNP, the log2ratio of the total (i.e. 
both alleles combined) probe intensities in the tumor to the total probe intensities in the matched 
non-malignant sample. The overlaid green dots show the segmentation (i.e. smoothing) of these 
data.  
(B, E) B allele frequency (BAF). Each red dot shows the proportion of non-reference alleles in 
the tumor sample at sites that are heterozygous in the matched non-malignant sample. As in 
panels A and B, the green dots show the segmentation of these data. Regions where the green 
dots are simultaneously displaced to values higher and lower than 0.5 are regions of LOH or 
allelic imbalance.  
(C, F) ASCAT estimates the genomic copy number of the two parental copies of each 
chromosome (arbitrarily colored red and green). Note that (the “green” copy) is completely 
deleted (copy number 0), leading to LOH. 
In both 990515 and 2000068, ASCAT estimates that one copy of chromosome 4 is completely 
lost (minor copy number is 0), and combined with the widely separated BAF data, we can infer 
LOH with copy loss at FAT4 in both two tumors from the ASCAT profile. 
*The graph was original produced by the author of the thesis and was utilized in the 








FIGURE 25. Comparison of RDAAC analysis using next-generation sequencing data and 
ASCAT analysis using Affymetrix SNP 6.0 data.   
(A) Analysis on next generation whole-exome sequencing data. (B) Analysis on Affymetrix SNP 
6.0 data.  
The top panel shows the logR ratio (LRR), which is the log2 of the ratio of the total signal 
intensity from the tumor data to the matched germ-line sample. Each red dot represents the LRR 
value at a site that is heterozygous in the germ-line, and the green dots show the segmentation of 
these data.  
The second panel is the B allele frequency (BAF) data, which shows the proportion of non-
reference alleles in the tumor sample at sites that are heterozygous in the germ-line sample.  The 
green dots also show the segmentation of these data. Regions where the green dots are 
simultaneously displaced to values higher and lower than 0.5 are regions of LOH or allelic 
imbalance. 
The third panel is the allelic-specific copy number that shows the estimated genomic copy 
number of the two parental copies of each chromosome (colored red: major allele copy number 
and green: minor allele copy number).   
The fourth panel is the aberration reliability score that shows ASCAT’s confidence in its 
estimates of chromosomal copy number at all locations that do not have one copy of each allele. 
The fifth panel is the predicted chromosome-segment counts before rounding to integer values. 
The bottom panel is the solution space, with the best score marked by “X”. 
*(A) was produced by Dr. John Richard McPherson. 
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CHAPTER 5 CONCLUDING REMARKS 
Gastric cancer is one of the leading causes of cancer death worldwide. Most cases are 
detected as advanced stage disease, at which point treatment options are few and usually 
of limited benefit. However, gastric cancer has been much less intensively studied than 
many other common tumors, and the molecular mechanisms of gastric cancer formation 
and progression remain poorly understood.  
CNA and LOH are common mutational events in gastric carcinogenesis. LOH is a 
key indicator of genomic instability and can be used to identify candidate tumor 
suppressor genes (TSGs). Studies of the spectrum of LOH in gastric cancer will improve 
our understanding of genetic alterations in gastric cancer tumors and identify possible 
new TSG.  
In this work, we developed a modified version of the Allele Specific Copy 
Number Analysis of Tumors (ASCAT) algorithm that improved analysis of Affymetrix 
SNP6 data. Compared to other algorithms and tools (Section 2.4.1), this analysis offers 
better ways to: 
(1) Analyze noisy data 
(2) Avoid genotyping errors 
(3) Estimate total and allele-specific copy number in samples from aneuploid tumors 
(4) Tackle samples with low tumor content 
We delineated the genome-wide landscape of CNA and LOH in gastric adenocarcinoma, 
including several regions, such as 9p and 17p, that frequently undergo LOH. The LOH 
landscape suggested the existence of novel TSGs, including PTPRD and DOCK8.  
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However, our functional analysis of these two genes failed to link their function to 
tumor proliferation. Therefore, further functional assays such as invasion and adhesion 
assays, are required to test their tumor suppressor functions.  
Although this study utilized data generated from Affymetrix SNP 6.0 arrays, the 
probes of which cover the whole cancer genome with high densities, we suspect that data 
from Illumina Infinium whole genome genotyping (WGG) arrays might be less noisy, 
based on our very limited experience with this latter chip (data not shown). Thus, 
introducing more tumor samples and a repetition of experiments on other platforms may 
provide a refinement of the results in this study.  
Furthermore, our experiences lead us to believe that there is still room for 
improvement in the development of algorithms for genome-wide assessment of CNA and 
LOH, especially using next-generation sequencing data, including use of whole-genome 
(as opposed to whole-exome) data, along with information on copy number breakpoints 
that whole-genome data can often provide. Beyond the basic studies of candidate TSGs, a 
comprehensive experimental analysis is required in subsequent studies to confirm the 
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